



FCT/G82004/002426



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport

South Wales

NP10 8QQ QCD 05 JUL 2004

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed


Dated 25 June 2004

BEST AVAILABLE COPY

1777

Request for grant of a patent

(see the notes on the back of this form. You can also get an explanatory leaflet from the Patent office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1 Your reference

2 Patent application number
(The Patent Office will fill in this part)

0402416.2

- 4 FEB 2004

3 Full name, address and postcode of the or of each applicant (underline all surnames)

JOHNSON MATTHEY PLC
2-4 Cockspur Street, Trafalgar Square, London, SW1Y 5BQPatents ADP Number (*if you know it*)

8519803001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4 Title of the invention

Ligands

5 Name of Your Agent (*if you have one*)

GIBSON, Sara Hillary Margaret

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)Johnson Matthey Catalysts
Intellectual Property Department
PO Box 1, Belasis Avenue
Billingham
Cleveland
England, TS23 1LBPatents ADP Number (*if you know it*)

8652166001

6 If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these

Country Priority Application number
(if you know it) Date of Filing
(day / month / year)

7 If this application is divided or otherwise derived from an earlier UK application, give the number and filing date of the earlier application

Number of earlier application Date of Filing
(day / month / year)

8 Is a statement of inventorship and of right to grant of a patent required in support of this request?

Yes

Answer yes if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See Note (d)

Patents Form 1/77

- 9 Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form -

Description 38

Claim(s) 3

Abstract 1

Drawings -

Sara H.M. Gibson

- 10 If you are also filing any of the following state how many against each item

Priority documents

Translations of priority documents

Statement of Invention and right to grant of a patent (*Patents Form 7/77*)

Request for Preliminary Examination and search (*Patents Form 9/77*)

Request for Substantive Examination (*Patents Form 10/77*)

Any other documents
(Please specify)

- 11 I/We request the grant of a patent on the basis of this application

Signature

Sara H.M. Gibson

Date

2.2.2004

- 12 Name and daytime telephone number of person to contact in the United Kingdom

Sara H.M. Gibson
01642 522650

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been issued, or any such direction has been revoked.

Notes


- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Ligands

This invention relates to ligands used in transition metal-catalysed asymmetric reactions and in particular to paracyclophanes more particularly to substituted paracyclophanes.


5 Paracyclophanes and in particular [2.2]-paracyclophane derivatives are established ligands for transition metal-catalysed asymmetric reactions (see for example, S. E. Gibson and J. D. Knight, *Org. Biomol. Chem.*, 2003, 1, 1256-1269). Of these, paracyclophane bis(phosphines) have attracted considerable attention because catalysts derived from them show high levels of activity and selectivity in a number of useful asymmetric transformations.

10 For example, WO 97/47632 describes paracyclophane bis(phosphine) ligands and rhodium (Rh), ruthenium (Ru), iridium (Ir) or palladium (Pd) catalysts derived therefrom for asymmetric hydrogenation, isomerization, hydroboration, cyclization, arylation, alkylation and amination reactions. The ligands described have the formula depicted below;



15 Where both X groups are the identical, these ligands posses C_2 symmetry, that is they are chiral and have a C_2 axis of symmetry. For example, the C_2 -symmetric [2.2] ligand where $X = -(\text{CH}_2\text{CH}_2)-$, known as PHANEPHOS, may be used in the asymmetric hydrogenation of ketones when comprising part of a Ru-diamine complex (see WO 01/74829).

20 WO 02/057278 describes paracyclophane ligands structurally related to the paracyclophane bis(phosphines) where the phenyl groups bound to the phosphorus in the [2.2]paracyclophane structure are replaced by oxygen, nitrogen, chloride or hydrogen atoms. These ligands are depicted below;



25 Rh, Ir and Ru catalysts derived therefrom were used in asymmetric hydrogenation reactions.


Whereas the paracyclophane ligands described are effective for many asymmetric transformations there is still a need to improve the activity and selectivity of catalysts derived

from them over a broader range of reactions and substrates. In addition, the paracyclophane ligands generally require lengthy and expensive resolution techniques in order to provide them in high enantiomeric purity for preparing catalysts for asymmetric transformations.

- 5 Furthermore, whereas the catalysts derived from the ligands described may be effective for providing acceptable activity and selectivity in these reactions when used as homogeneous catalysts, they are not particularly amenable to immobilisation on solid supports. The fixing of homogeneous catalysts to solid supports provides the potential for extending the benefits of heterogeneous catalysts to homogeneous systems. These benefits include easier separation
10 of catalyst and reaction products leading to shorter work up times and improved process efficiency, the potential for re-activation and re-use of the supported catalysts which are often based on expensive metals and complex ligand geometry, and the possible adaptation of the immobilised catalyst to continuous flow fixed-bed processes.
- 15 We have found that by providing a substituting group on one or both of the benzene rings in a paracyclophane structure that electronic and/or steric properties of the ligand may be altered to better suit different reactions or reaction conditions. Furthermore, the substituting group may also be used to facilitate chiral resolution of the paracyclophane and if desired to provide a functional group suitable for reaction with a solid support material.

20

Accordingly the present invention provides a substituted paracyclophane of formula (I)



- wherein X^1 and X^2 are linking groups comprising between 2 to 4 carbon atoms, Y^1 and Y^2 are selected from the group consisting of hydrogen, halide, oxygen, nitrogen, alkyl, cycloalkyl, aryl or heteroaryl, Z^1 , Z^2 and Z^3 are substituting groups that optionally contain functional groups,
25 wherein a, b, c, d, e and f are 0 or 1 and $a + b + c + d + e + f = 1$ to 6.

- Linking groups X^1 and X^2 provide links between the benzene rings of the paracyclophane structure that comprise between 2 and 4 carbon atoms. Hence X^1 and X^2 may be linear, branched or cyclic structures where the link is formed via 2, 3 or 4 carbon atoms. The links may, in addition to the carbon atoms, contain heteroatoms such as O, N or S (where the N atom may in turn be bonded to an alkyl group such as CH_3 , C_2H_5 , C_3H_7 or C_4H_9 or an aryl group, and the S atom may be bonded to an alkyl or aryl group or be part of an SO or SO_2

- moiety) and/or the carbon atoms in the linking group may be substituted with a halide, e.g. one or more fluorine atoms. Hence linking groups X^1 and X^2 may independently be for example $-(CH_2)_{2-4}-$, $-CH_2OCH_2-$, $-CH_2N(CH_3)CH_2-$, $-CH_2SO_2CH_2-$, $-C_2F_4-$ or ortho, meta or para $-C_6H_4$. Such modification of the linking group may be useful for adapting the substituted
- 5 paracyclophane to different reaction conditions, e.g. solvents. Preferably the linking groups comprise $-(C_2H_4)-$, $-(C_3H_6)-$ or $-(C_4H_8)-$. More preferably X^1 and X^2 are the same and most preferably X^1 and X^2 are both $-(C_2H_4)-$.

In one embodiment the paracyclophane is a bis(phosphine) where Y^1 and Y^2 may independently be hydrogen, halide (Cl, Br, F or I) or straight chain or branched alkyl groups (e.g. C1-C20) such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, and stearyl, cycloalkyl groups (e.g. C3-C10) such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or aryl groups such as phenyl, naphthyl or anthracyl. The alkyl groups may be optionally substituted with one or more substituents such as halide (Cl, Br, F or I) or alkoxy groups, e.g. methoxy, ethoxy or propoxy groups. The aryl groups may be optionally substituted with one or more substituents such as halide (Cl, Br, F or I), methyl, trifluoromethyl or methoxy groups. Suitable substituted aryl groups include 4-methylphenyl, 3,5-dimethylphenyl, 4-methoxyphenyl and 4-methoxy-3,5-dimethylphenyl. Substituted or unsubstituted heteroaryl groups such as pyridyl may also be used.

- In an alternative embodiment, Y^1 and Y^2 on each phosphorus atom may be linked so as to form a ring structure incorporating the phosphorus atom. In such an embodiment, preferably Y^1 and Y^2 are linked so as to provide each phosphorus atom in a 4- to 7-membered ring.
- 25 In yet a further embodiment, the paracyclophane may be a phosphonite (where Y^1 and Y^2 are oxygen atoms), a phosphorus-amide (where Y^1 and Y^2 are nitrogen atoms), or a phosphonamidite (where Y^1 is an oxygen atom and Y^2 is a nitrogen atom).
- 30 Preferably, Y^1 and Y^2 are the same and are phenyl or substituted phenyl groups.

Substituting groups Z^1 , Z^2 and Z^3 depending upon their number and position replace hydrogen atoms on one or both benzene rings of the paracyclophane (I). Z^1 , Z^2 or Z^3 may independently be non-functional group-containing substituting groups such as branched or linear alkyl (e.g. C1-C30) or aryl (e.g. phenyl, naphthyl or anthracyl). Such non-functional group-containing substituting groups may be effective in altering the physical, electronic and/or steric properties of the paracyclophane for example where the paracyclophane is used as part of a homogeneous transition metal catalyst complex. Alternatively Z^1 , Z^2 or Z^3 may be functional group-containing substituting groups that comprise one or more functional groups that may, if




desired, be used to facilitate chiral resolution of the paracyclophane ligand or an intermediate thereof and/or covalently bond the paracyclophane ligand (or an intermediate thereof) and hence a catalyst derived therefrom, to a suitably reactive solid support. Functional group-containing substituting groups Z^1 , Z^2 and Z^3 may independently comprise one or more

- 5 functional groups selected from halide (Cl, Br, F or I), hydroxyl, alkoxy (e.g. C1-C30), carbonyl, carboxyl, anhydride, methacryl, epoxide, vinyl, nitrile, nitro, sulphate, sulphonyl, mercapto, sulphide amino, amine, imine, amide and imide. These functional groups may, where appropriate, be directly bonded to the benzene ring in the paracyclophane ligand or may be present in alkyl (e.g. C1-C30), aryl or alkyl-aryl groups bonded to the benzene ring. In addition
- 10 Z^1 , Z^2 or Z^3 on one benzene ring in the paracyclophane structure may be the same or different from Z^1 , Z^2 or Z^3 on the other benzene ring, i.e. $(Z^1)_a$, $(Z^2)_b$ and $(Z^3)_c$ may be the same or different from $(Z^1)_d$, $(Z^2)_e$ and $(Z^3)_f$. Preferred substituting groups are -CH₃ (Me), -C(CH₃)₃ (tBu), -CH(CH₃)₂ (iPr), -C₆H₅ (Ph), -CH=CH₂, -I, -NO₂, -N=CPh₂, R'OCH₂- or R'O- (where R' = CH₂Ph, CH₃, tBu, iPr, Si(tBu)Me₂ or Si(iPr)₃); R''O₂C- (where R'' = H, CH₃, Ph-CH₂, tBu, iPr, preferably H); and R'R''N-, R'R''NCH₂- or R'R''NCO- (where R' and/or R'' = H, CH₃, CH₂Ph).
- 15




The substituting group on each benzene ring in the paracyclophane structure may be in an ortho (Z^3), meta (Z^2) and/or para (Z^1) position to the P(Y¹Y²) group. When the substituent is at the para-position of the benzene ring it may enhance the electronic effects on the P(Y¹Y²) group and permits, by choice of suitable Z^1 substituents the possibility of electronic fine-tuning of the ligand to enhance its effect when part of a catalyst for different reactions and substrates. By careful choice of the Z^2 or particularly the Z^3 substituent in the ortho-position, the steric properties of the ligand may be altered to effect changes in catalyst selectivity. The substituting groups may also be used to alter the physical properties of the paracyclophane e.g. its stability in air, towards water, or its solubility in different solvents.

- 20
 - 25
 - 30
 - 35
- At least one and up to six substituting groups may be present on the substituted paracyclophane (I) of the present invention. While each benzene ring in the paracyclophane structure may comprise three substituting groups, it is preferred that each benzene ring comprises one or two substituting groups such that $a + b + c + d + e + f = 1$ to 4, more preferably $a + b + c + d + e + f = 1$ or 2. Most preferably each benzene ring comprises only one substituting group, i.e. $a + b + c = 1$ and / or $d + e + f = 1$. It will be understood by those skilled in the art that when a substituting group is absent, i.e. where a, b, c, d, e or $f = 0$ then the corresponding carbon atom of the benzene rings in the paracyclophane will be bound to a hydrogen atom.


Paracyclophanes of the present invention, suitable for use as ligands for the preparation of catalysts, include but are not restricted to the following;



$R = \text{Ph, Tol, Xyl, MeO-Xyl, MeO-Ph, } i\text{-Pr, c-Hex, } t\text{-Bu}$ $R''R'''N = \text{NH}_2, \text{NHMe, NH(CH}_2\text{Ph), NMe}_2, \text{N(CH}_2\text{Ph})_2$



where, $R' = \text{CH}_2\text{Ph, CH}_3, t\text{-Bu, } i\text{-Pr, Si}(t\text{-Bu})\text{Me}_2, \text{Si}(i\text{-Pr})_3$



where $R = \text{Trityl, Ph, Tol, Xyl, MeO-Xyl, MeO-Ph, } i\text{-Pr, c-Hex, } t\text{-Bu}$

$R' = \text{CH}_2\text{Ph, CH}_3, t\text{-Bu, } i\text{-Pr, Si}(t\text{-Bu})\text{Me}_2, \text{Si}(i\text{-Pr})_3$,

and     


Tol Xyl MeO-Xyl MeO-Ph c-Hex

Methods for preparing the paracyclophane of the present invention include electrophilic substitution (including Friedel Crafts alkylation and acylation reactions), nucleophilic substitution, and metallation-substitution reactions on a suitable paracyclophane intermediate. Alternatively the substituted paracyclophane may be constructed by coupling or dimerisation of suitably substituted and functional benzene ring units by e.g. thermal or photochemical means.


Preferably the substituted paracyclophane of the present invention is prepared by substitution reactions on a suitable paracyclophane intermediate. In particular, we have found that substituted pseudo-ortho dibromo-paracyclophane provides a very useful starting point for the synthesis of the substituted paracyclophane of the present invention.

10

Accordingly, the present invention further provides a method for preparation of a substituted paracyclophane of formula (I) by,



(a) performing a substitution reaction on a pseudo-ortho dibromoparacyclophane to form an intermediate substituted pseudo-ortho dibromoparacyclophane of formula (II), and




(b) reacting the substituted pseudo-ortho dibromoparacyclophane with a phosphorus compound comprising $P(Y^1Y^2)$, wherein X^1 and X^2 are linking groups comprising between 2 to 4 carbon atoms, Y^1 and Y^2 are selected from the group consisting of hydrogen, halide, oxygen, nitrogen, alkyl, cycloalkyl, aryl or heteroaryl, Z^1 , Z^2 and Z^3 are substituting groups that optionally contain functional groups, wherein a , b , c , d , e and f are 0 or 1 and $a + b + c + d + e + f = 1$ to 6.

The pseudo-ortho dibromoparacyclophane from which the substituted dibromoparacyclophane (II) is synthesised may be prepared according to known methods. Typically a paracyclophane may be reacted with bromine in the presence of iron in a suitable solvent (see D. J. Cram et al, *J. Am. Chem. Soc.*, 1969, 91, (13), 3527). In particular, for commercially available [2.2]paracyclophane, the synthesis of the pseudo-ortho dibromo[2.2]paracyclophane may be

performed according to the methods described in example 1 and example 2 on pages 31 and 32 of aforesaid WO 97/47632.


Electrophilic substitution reactions are preferred for preparing the substituted paracyclophane
 5 of the present invention. In particular, we have found that the Lewis-acid mediated electrophilic substitution of a pseudo-ortho dibromoparacyclophane, particularly the pseudo-ortho dibromo[2.2]paracyclophane, proceeds surprisingly to substantially only the mono-para-substituted reaction product in high yield and selectivity. By forming only a mono-substituted product, the method is highly efficient and overcomes the possibility of having to perform
 10 complex and expensive separation techniques to obtain the desired substituted paracyclophane product.

For example, acetylation of pseudo-ortho dibromo[2.2]paracyclophane proceeds smoothly in the presence of aluminium trichloride (AlCl_3) and acetyl chloride (CH_3COCl) in dichloromethane (DCM) and surprisingly affords the mono-substituted acetylated product, with the ketone group exclusively in the para position. Even in the presence of excess Lewis acid no di-acetylated product was obtained. This reaction is depicted below;




Scheme 1

20 In the presence of oxalyl chloride and AlCl_3 the pseudo-ortho dibromo[2.2]paracyclophane mono-acid chloride can be produced in high yield. This can either be hydrolysed in the presence of water or quenched with the methanol to give the methyl ester. These reactions are depicted below;




Scheme 2

Under standard nitration conditions (conc HNO₃/acetic anhydride) both mono- and di-substituted pseudo-ortho dibromo[2,2]paracyclophane compounds could be obtained as well as some decomposition of the starting material. However, under preferred Lewis Acid nitration conditions (Sc(OTf)₃) a higher yield of the pseudo-ortho dibromo[2,2]paracyclophane mono-nitro compound was obtained with no di-substituted product detected. These reactions are depicted below;



Scheme 3

- Ortho-substitution may be accomplished using a method of ortho-lithiation wherein a paracyclophane substituted with an ortho-directing group, e.g. 4-N,N-diethylamido-[2,2]paracyclophane is lithiated using a suitable alkyl-lithium compound, e.g. t-butyl lithium in diethyl ether and TMEDA, and the resulting lithiated paracyclophane treated with a suitable electrophile (see Pelter et al, *Tetrahedron Lett.*, 2001, 8391-4).
- The functional groups on the substituted pseudo-ortho dibromoparacyclophane (II) may, if desired, be chemically transformed before it is converted into the desired phosphine, phosphonite, phosphorus-amide or phosphonamidite-containing paracyclophane of formula (I). For example, where the substituting group is a nitro (-NO₂) group it may be reduced using known techniques such as catalytic hydrogenation to an amino (-NH₂) group. Alternatively, a hydroxyl functionality may be provided by reduction of e.g. the methyl ester product depicted in Scheme 2 using LiAlH₄ to give the corresponding benzyl alcohol. However, prior to conversion of the benzyl alcohol-substituted pseudo-ortho dibromoparacyclophane into the corresponding phosphine, phosphonite or phosphonamidite, the hydroxyl group may be converted to another substituting group, e.g. a trityl group or tri-isopropoxysilyl group. The trityl-conversion reaction is depicted below.



Scheme 4


If desired the hydroxyl functional group may be regenerated from the trityl group by treatment of the resulting trityl-functionalised substituted paracyclophane with a suitable acid. Similarly, the tri-isopropylsilyl group may be removed using tetrabutylammonium fluoride (TBAF).

5

Once the substituted pseudo-ortho dibromoparacyclophane (II) has been synthesised, the next step of the method of the present invention is the conversion of the pseudo-ortho bromide groups to the desired phosphine, phosphonite, phosphorus amide or phosphonamidite by reacting the substituted pseudo-ortho dibromoparacyclophane (II) with a phosphorus

- 10 compound comprising $P(Y^1Y^2)$. This reaction may be performed according to a number of known methods. For example direct displacement of the Br atoms by diphenylphosphino groups may be achieved by reaction of the substituted pseudo-ortho dibromoparacyclophane (II) with diphenylphosphine (Ph_2PH) in the presence of $NiCl_2.dpe$ and triethylenediamine in DMF at $100^\circ C$, or by using the lithiated diphenylphosphine (Ph_2PLi) with $NiCl_2.dpe$ in THF at 15 room temperature. Alternatively, a low temperature lithiation with $BuLi$ and transmetallation using $MgBr_2$ leads to an active Grignard reagent that may be combined with the more stable phosphoryl oxide ($Ph_2P(O)Cl$). The Grignard may also be formed directly by reaction of Mg with the substituted pseudo-ortho dibromide (II). The resulting bis(phosphine oxide) paracyclophane is then reduced to the desired bis phosphine using a suitable reducing agent, 20 e.g. $HSiCl_3$ or $LiAlH_4$.

Preferably, substituted paracyclophane bis(phosphines) are prepared by treating the substituted pseudo-ortho dibromoparacyclophane of formula (II) with an alkyl lithium reagent, e.g. tert-Butyl Lithium ($tBuLi$) and the anion quenched with an aryl- or alkyl-phosphinylchloride, 25 e.g. diphenylphosphinylchloride (Ph_2PCl) to give the desired substituted paracyclophane bis(phosphine). A similar method may be used for other aryl and alkyl phosphines. Using the trityl-protected pseudo-ortho dibromo[2,2]paracyclophane of Scheme 4, this reaction may be depicted as follows;




Scheme 5

Alternatively, the more air and moisture-stable corresponding phosphine oxide may be prepared using Ph_2POCl and the phosphine oxide subsequently reduced using e.g. HSiCl_3 .

- 5 Methods suitable for preparing a phosphonite, phosphorus amide and phosphonamidite from the substituted pseudo-ortho dibromoparacyclophane of formula (II) may be found in A. Zanotti-Gerosa et al, *Org. Lett.*, 2001, 3687.

A substituted pseudo-ortho dibromoparacyclophane may be converted to the corresponding 10 substituted paracyclophane bis(phosphonite) in an analogous manner to the phosphine by direct metallation of the dibromide with a strong organometallic base and reaction with the appropriate chloro-phosphonite. Preferably, the substituted paracyclophane bis(phosphonite) may be synthesised by treatment of a substituted paracyclophane bis(dichlorophosphine) or substituted paracyclophane phosphorus-diamide with an alcohol, diol or metal diolate. The 15 substituted paracyclophane bis(dichlorophosphine) may itself be obtained via the paracyclophane phosphorus diamide which may be prepared by direct metallation of the paracyclophane dibromide with a strong organometallic base and reaction with a chloro-phosphorus-diamide such as $\text{Cl-P}(\text{NCH}_3)_2$ or $\text{ClP(iso-C}_3\text{H}_7)$. The resulting paracyclophane phosphorus-diamide may be converted to the paracyclophane bis(dichlorophosphine) by 20 treatment with an HCl solution. These reactions are depicted for a substituted [2.2] paracyclophane below;




Scheme 6

To prevent unwanted side reactions during the described sequence of reactions, the substituting group may where appropriate be protected, e.g. by an alkoxy group using known methods.

- 5 The substituted paracyclophane of the present invention is chiral and may adopt one of two enantiomeric forms i.e. an (R)- or (S)-configuration. Accordingly, the paracyclophane may comprise a racemic mixture of enantiomers. Alternatively and preferably the substituted paracyclophane comprises a substantially enantiomerically-pure enantiomer (i.e having an enantiomeric excess >75%, preferably >95%). To obtain a substantially pure enantiomer the 10 substituted paracyclophane may be prepared from a substantially enantiomerically-pure pseudo-ortho dibromoparacyclophane starting material. For example, resolution of a racemic mixture of pseudo-ortho dibromoparacyclophane may be effected on a chiral stationary phase such as crystalline cellulose triacetate using ethanol as eluant or on chiral HPLC columns. Alternatively, a chiral resolution may be performed at later stages during the synthetic process.
- 15 For example, the resolution may be performed on the substituted paracyclophane bis(phosphine), phosphine oxide, phosphonite, phosphorus amide or phosphonamidite (I) using known crystallisation techniques or separation on chiral chromatography columns. For example, resolution may be effected by treatment of a substituted paracyclophane phosphine oxide to form inclusion complexes with chiral substances such as benzoyl tartaric acid: the 20 resolved phosphine oxide then is reduced using e.g. HSiCl_3 . These methods however have a disadvantage in that they can be expensive and time-consuming.

Advantageously, in the present invention, the chiral resolution of the paracyclophane may, if desired, be achieved utilising the substituting group itself. This resolution is preferably 25 performed using a substituted pseudo-ortho dibromoparacyclophane having a suitable functional group on a substituting group.

Accordingly, the invention further provides a substituted pseudo-ortho dibromoparacyclophane of formula (III)




30

wherein X^1 and X^2 are linking groups comprising between 2 to 4 carbon atoms, Z^1 , Z^2 and Z^3 are functional group-containing substituting groups that comprise one or more functional groups selected from hydroxyl, alkoxy, carboxyl, anhydride, methacryl, epoxide, vinyl, nitrile,

nitro, sulphate, sulphonyl, mercapto, sulphide amino, amine, imine, and imide, a, b, c, d, e and f are 0 or 1 and $a + b + c + d + e + f = 1$ to 6.

Preferably the functional group is a carboxylic acid (-COOH) functional group that may be reacted with a chiral base, or an amino functional group (-NH₂, formed for example by reduction of a nitro, -NO₂, group) that may be reacted with a chiral acid. Alternatively, the functional group may be one that may interact with an enzyme to allow enzymatic chiral resolution. Preferably one or two, more preferably one functional group-containing substituting group is present in the substituted pseudo-ortho dibromoparacyclophane of formula (III), i.e. preferably $a + b + c + d + e + f = 1$ or 2, more preferably $a + b + c + d + e + f = 1$.

The use of the substituted pseudo-ortho dibromoparacyclophane of formula (III) provides a number of advantages, in particular the simplification of the synthetic process to the desired chiral product. In one embodiment, the mono-substituted paracyclophane carboxylate of Scheme 2 may be used to effect chiral resolution of the pseudo-ortho dibromide before synthesis of the paracyclophane phosphine, phosphonite, phosphorus-amide or phosphonamidite. The sequence of steps leading to chiral resolution of a mono-para-substituted pseudo-ortho dibromo[2.2]paracyclophane using a chiral base is depicted below;




Scheme 7

The chiral resolution may be effected using known techniques using a chiral base such as cinchonidine. Alternatively, the resolution may be performed on an amino-substituted pseudo-ortho dibromoparacyclophane using a chiral acid e.g. tartaric acid and tartaric acid esters, mandelic acid or camphor sulphonc acid.

It will be understood by those skilled in the art that where one enantiomer of a substituted paracyclophane is depicted, the other is included within the scope of the present invention.

The substituted paracyclophane (I) of the present invention may be used as a ligand to prepare metal complexes suitable for use as catalysts in chemical reactions.

Accordingly the invention further provides a metal complex comprising the reaction product of a
5 metal compound and a substituted paracyclophane of formula (I)




wherein X¹ and X² are linking groups comprising between 2 to 4 carbon atoms, Y¹ and Y² are selected from the group consisting of hydrogen, halide, oxygen, nitrogen, alkyl, cycloalkyl, aryl or heteroaryl, Z¹, Z² and Z³ are substituting groups that optionally contain functional groups, a, b, c, d, e and f are 0 or 1 and a + b + c + d + e + f = 1 to 6.
10

The substituted paracyclophane (I) may be combined with the metal compound in a racemic mixture or in a substantially enantiomerically pure form. Preferably the substituted paracyclophane (I) is substantially enantiomerically-pure (i.e having an enantiomeric excess >75%, preferably >95%). The metal compound may be any metal compound that is able to react with the substituted paracyclophane (I) to provide a metal complex. The metal compound is preferably a compound of palladium (Pd), platinum (Pt), rhodium (Rh), iridium (Ir) or ruthenium (Ru) which may be a metal salt, e.g. halide, carboxylate, sulphonate or phosphonate, or an organometallic compound. The metal complex may additionally comprise ligands that are able to reversibly co-ordinate. Reversibly co-ordinating ligands may improve the stability of the metal complexes and may be provided during the synthesis of the metal complex or may react with the metal complex when it is added to the reaction mixture. By "reversibly co-ordinating" we mean a ligand that can be readily displaced by other molecules in a reaction mixture. Such reversibly co-ordinating ligands may be selected from the list comprising dienes, particularly cyclic dienes such as cyclooctadiene or norbornadiene, C1-C4 alcohols, ethers, cyclic ethers, diols, e.g. 1,2-diols and C2 or C3 olefins, e.g. ethylene. In addition, the metal complex may additionally comprise a non-reversibly co-ordinating ligand that may be used to modify the reactivity and selectivity of the metal complex catalyst. Non-reversibly co-ordinating ligands that may be used particularly in Rh complexes are diamines, for example 1,2-diphenylethylenediamine, 1,2-cyclohexylethylenediamine and ethylene diamine and particularly substantially enantiomerically-pure 1,2-diamines such as (S,S)-1,2-diphenylethylenediamine.
15
20
25
30

To satisfy the oxidation state of the metal complex, it may when the oxidation state of the metal requires, further comprise a counter-ion. The counter-ion may be any suitable anion but is preferably a non-nucleophile anion selected from trifluoromethanesulphonate (triflate or OTf), perchlorate (ClO₄⁻), hexafluoroantimonate (SbF₆⁻) or hexafluorophosphate (PF₆⁻).

5


Accordingly, metal complexes of the present invention include but are not limited to the following:




where

M = Rh, Ir

X = BF₄⁻, PF₆⁻, OTf




R = Ph, Tol, Xyl, MeO-Xyl, MeO-Ph, i-Pr, c-Hex, t-Bu
R' = Trityl, CH₂Ph, CH₃, t-Bu, i-Pr, Si(t-Bu)Me₂, Si(i-Pr)₃,



10 The metal complexes may be readily prepared from the substituted paracyclophane of the present invention. In general, the metal compound is combined with the substituted paracyclophane and optionally the reversibly co-ordinating ligand and/or non-reversibly co-ordinating ligand in a suitable solvent and heated if necessary to form the desired metal


complex. For example, the alkoxy-substituted paracyclophane bis(phosphine) of Scheme 5 reacts under relatively mild conditions with $[\text{RuCl}_2(\text{benzene})_2]_2$ and (S,S)-Dopen to form a catalyst suitable for performing asymmetric reduction reactions. This reaction is depicted below.



5 Scheme 8

The substituted paracyclophane ligands of the present invention are chiral and therefore are able to produce chiral metal complex catalysts. The chiral metal complex catalysts of the present invention may be applied to a large number of asymmetric reactions used to produce 10 chiral products. Such reactions include but are not limited to the chiral hydrogenation of enamide and non-enamide structures, asymmetric hydrogenation in iso-quinoline synthesis, the asymmetric hydrogenation of unsaturated alcohols, asymmetric hydrogenation of ketones and imines, enantioselective isomerization of olefins, asymmetric hydroboration reactions, asymmetric cyclisation of olefinic aldehydes, asymmetric arylation and alkylation reactions and 15 the amination of aryl halides (Hartwig-Buchwald reaction). To achieve high levels of enantiomeric purity in the reaction it is preferred that the metal complex comprises a substantially enantiomerically-pure substituted paracyclophane (I).

The conditions for using the metal complex catalysts are typically similar to those used for 20 structurally related catalysts. For example, for the asymmetric reduction of ketones, the catalyst prepared according to scheme 7 may be used at room temperature under standard hydrogen pressures. The reaction may be depicted as follows;



Scheme 9

25 While we have found the metal complexes comprising substituted paracyclophanes of the present Invention to be highly effective homogeneous catalysts we have found also that the

metal complexes may be provided supported on solid supports as heterogeneous catalysts. Heterogeneous catalysts have the advantages that they are often easier to separate from the reaction mixtures and may in some circumstances be recycled. To form a heterogeneous catalyst, the metal complex may be absorbed or ion-exchanged into a suitable solid support

- 5 material, e.g. a zeolite. Alternatively the metal complex may be reacted with functional groups present on a solid support material to form a covalently bound catalyst. Covalently-bound heterogeneous catalysts are preferred as they can be more resistant to leaching of the metal complex in use than the absorbed or ion-exchanged heterogeneous catalysts.
- 10 Advantageously, the substituted paracyclophanes of the present invention possess substituting groups that may contain functional groups that are capable of reacting with functional groups present on the solid support material.

A number of routes are possible for forming a covalently-bound heterogeneous catalyst using the paracyclophanes of the present invention.

- 15 (i) the metal complex derived from substituted paracyclophane (I) having functional group-containing substituting groups may simply be reacted with functional groups present on the insoluble solid support material.
- (ii) The substituted paracyclophane (I) having functional group-containing substituting groups may be reacted with functional groups present on an insoluble solid support
- 20 material and the metal compound subsequently reacted with it to prepare a supported metal complex:
- (iii) The substituted dibromoparacyclophane (II) having functional group-containing substituting groups may be reacted with the functional groups present on a solid support material and then converted to the substituted paracyclophane (I) before
- 25 subsequently reacting the supported paracyclophane with the metal compound to form the supported metal complex.

Furthermore, if a functional group present in substituting groups Z¹, Z² or Z³ is unsuitable for reaction with a given solid support material, it may be inter-converted by chemical reaction (e.g. reduction or oxidation) or alternatively, the functional group may be reacted with a linker molecule that provides a suitable functional group capable of reaction with said solid support.

The solid support materials to which the substituted paracyclophane may be covalently bonded, may be polymers, metal oxides or sol-gel materials that have sites capable of reacting

35 with functional groups present in substituting groups Z¹, Z² or Z³. The reactive sites present in the solid support materials may be selected from halide (Cl, Br, F, or I), hydroxyl, carbonyl, carboxyl, anhydride, methacryl, epoxide, vinyl, nitrile, mercapto, isocyanate, amine, imine, amide and imide, and are typically provided by surface functionalisation of the solid supports using known methods, e.g. grafting using organofunctional silanes. The metal oxides include

silica, titania, zirconia or alumina, alumino-silicates or mixtures of these. The polymer may be any thermoplastic polymer that is insoluble in the solvent system used for performing the catalysed reaction and is stable under the reaction conditions. Preferably, where the reaction is performed in polar solvents, the polymer is a polyolefin copolymer, for example a

5 polystyrene-acrylate copolymer of suitable molecular weight. Such polymers contain carboxyl (COOH) groups able to react with e.g. a hydroxyl (OH) or an amine (NH_2) group present in substituting groups Z^1 , Z^2 or Z^3 . By the term "sol-gel materials" we mean organofunctional

10 silica materials prepared, for example, by hydrolysis of organofunctional silanes, preferably in the presence of alkyl silicates and optionally other metal alkoxides, for example according to the methods described in WO 02/066159.


The solid support material may be in the form of powder, pellets, granules, fibres, a honeycomb or foam.

15 The invention is further illustrated by reference to the following examples where MTBE = methyl-t-butyl ether; DMF = dimethylformamide; DMAP = 2,6-dimethylaminopyridine Dpen = 1,2-Diphenylethylenediamine; NBD = norbornadiene, DBU = 1,8-diazabicyclo-[5.4.0]-undec-7-ene and room temperature = 20-25°C unless otherwise stated. The nomenclature of the substituted paracyclobanes was assigned as in: S. Gisbon et al. *Organic and*

20 *Biomolecular Chemistry* 2003, 1256.

Example 1. Synthesis of nitro [2.2]paracyclophane derivatives

a) Standard nitration: preparation of 4,12-dibromo-7-nitro[2.2]paracyclophane and 4,12-dibromo-7,15-dinitro[2.2]paracyclophane.



25 A solution of HNO_3 conc. (0.6 mL) in acetic anhydride (1.4 mL) was added to a suspension of 4,12-dibromo[2.2]paracyclophane (1.098 g, 3 mmol) in acetic anhydride (2 mL) cooled to 0°C. The reaction was stirred at room temperature for 1,5 hours. The resulting yellow solution was diluted with water (100 mL) and extracted with ethyl acetate (2 x 50 mL). The combined

30 organic layers were washed with more water, dried over anhydrous Na_2SO_4 and evaporated to give a yellow oil that was purified by chromatography (eluant: hexane/ethyl acetate 19/1) to give 4,12-dibromo-7-nitro-paracyclophane (105 mg, 8.5 % yield) and 4,12-dibromo-7,15-dinitro-paracyclophane (110 mg, 8% yield).

b) Lewis acid mediated nitration: preparation of 4,12-dibromo-7-nitro[2.2]paracyclophane

Sc(OTf)₃ (100 mg, 0.2 mmol) was suspended in dichloroethane (2.5 mL) and HNO₃ 70% (0.1 mL) was added to give a clear solution at room temperature. 4,12-Dibromo-

5 [2.2]paracyclophane (366 mg, 1 mmol) was added and the reaction was heated to 70°C and stirred for 20 hours. After this time, thin-layer chromatographic (TLC) analysis (eluent: hexane/MTBE 95/5) indicated that the reaction was not complete and more Sc(OTf)₃ (100 mg, 0.2 mmol) and HNO₃ 70% (0.1 mL) were added. After 1 hour at 70°C all the starting material was consumed and the reaction was diluted with dichloromethane (50 mL) and washed with brine (2x50 mL). The organic phase was dried over anhydrous Na₂SO₄ and evaporated to give

10 a yellow oil. The crude material was dissolved in 2 mL dichloromethane and eluted through a pad of silica gel (eluent hexane/MTBE 9/1). Evaporation of the solvent gave 4,12-dibromo-7-nitro[2.2]paracyclophane (190 mg, 31% yield) as a yellow solid.


4,12-dibromo-7-nitro[2.2]paracyclophane: ¹H NMR (CDCl₃, 400 MHz): 2.75 (1H, m, -CH₂-), 3.0 (4H, m, -CH₂-), 3.4 (2H, m, -CH₂-), 3.3 (1H, m, -CH₂-), 6.4 (1H, d, CH arom), 6.6 (1H, d, CH arom), 7.1 (1H, s, CH arom), 7.25 (1H, s, CH arom), 7.3 (1H, s, CH arom) ppm. ¹³C NMR (CDCl₃, 400MHz): 32.1 (-CH₂-), 32.6 (-CH₂-), 35.1 (-CH₂-), 35.2 (-CH₂-), 127.0 (C arom), 130.9 (CH arom), 131.2 (CH arom), 132.0 (CH arom), 132.6 (C arom), 133.3 (CH arom), 136.2 (CH arom), 137.7 (C arom), 138.9 (C arom), 140.9 (C arom), 141.4 (C arom), 148.6 (C-NO₂ arom) ppm.

20 4,12-dibromo-7,15-dinitro[2.2]paracyclophane: ¹H NMR (CDCl₃, 400 MHz): 3.1 (4H, m, -CH₂-), 3.4 (2H, m, -CH₂-), 3.8 (2H, m, -CH₂-), 7.3 (4H, s, broad, CH arom) ppm. ¹³C NMR (CDCl₃, 400MHz): 30.9 (-CH₂-), 33.4 (-CH₂-), 126.9 (CH arom), 131.6 (C arom), 135.5 (CH arom), 135.7 (C arom), 140.4 (C arom), 147.4 (C-NO₂ arom) ppm.

Example 2. Synthesis of acetyl [2.2] paracyclophane derivatives


25

a) Preparation of 7-acetyl-4,12-dibromo[2.2]paracyclophane.




A solution of AlCl₃ (266 mg, 2 mmol) and acetyl chloride (0.145 mL, 2 mmol) in anhydrous dichloromethane CH₂Cl₂ (2.5 ml) was added to a solution of (R)-4,12-dibromoparacyclophane (366 mg, 1 mmol) in CH₂Cl₂ (10 ml) at -45°C. The mixture was allowed to warm to room temperature. After 30 mins the reaction mixture was poured into a flask containing dilute 2M aq. HCl (50 ml) and ice. Methyl-t-butyl ether MTBE (50 ml) was added and the organic layer further washed with saturated solution of NaHCO₃ (50 ml), brine (50 ml) and dried further with anhydrous MgSO₄, filtered and the solvent removed to give the crude product which was


35 substantially pure by NMR.

Example 3. Synthesis and resolution of carboxylic acid [2.2]paracyclophane derivativesa) Preparation of 7-chlorocarbonyl-4,12-dibromo[2.2]paracyclophane

- 5 Oxalyl chloride (0.35 mL, 4 mmol) was added dropwise to a suspension of AlCl₃ (260 mg, 2 mmol) in CH₂Cl₂ (2 mL). After stirring for 30 min at room temperature, the obtained solution was cooled down to 0 °C and treated with a solution of (R)-4,12-dibromo[2.2]paracyclophane (366 mg, 1 mmol) in CH₂Cl₂ (2 mL). The dark solution was then stirred at 0 °C for 30 min and allowed to warm up to room temperature for another 30 min. Solvents and volatile reagents
10 were removed under vacuum to afford the product as a yellow solid.

b) Preparation of 4,12-dibromo-7-methoxycarbonyl [2.2]paracyclophane


- A solution of 7-chloroformyl-4,12-dibromo[2.2]paracyclophane (1 mmol) in CH₂Cl₂ (2 mL) was
15 treated with methanol, MeOH (3 mL) and stirred at 50 °C for 1 hour. After cooling down to room temperature and diluting with MTBE (10 mL), the organic phase was washed with 2.8 M NH₄Cl, H₂O and saturated aqueous NaHCO₃, dried over anhydrous MgSO₄ and concentrated under vacuum to afford the product (360 mg, 85% yield) as a pale yellow solid (mp = 118.7 °C). ¹H NMR (CDCl₃): 2.7-2.8 (m, 1H), 2.8-3.0 (m, 4H), 3.2-3.4 (m, 2H), 3.85 (s, 3H, CO₂CH₃), 3.7-3.9 (m, 1H), 6.38 (d, 1H, J = 7.8 Hz), 6.43 (d, 1H, J = 7.8 Hz), 7.10 (s, 1H), 7.11 (s, 1H), 7.17 (s, 1H) ppm. ¹³C NMR (CDCl₃): 32.2 (t), 32.7 (t), 35.4 (t), 35.5 (t), 52.0 (q), 126.6 (s), 130.3 (s), 131.1 (s), 131.2 (d), 132.8 (d), 133.3 (d), 135.1 (d), 136.8 (d), 139.1 (s), 139.2 (s), 141.0 (s), 144.0 (s), 166.8 (s, CO) ppm.

c) Preparation of 4,12-dibromo-7-tert-butoxycarbonyl [2.2]paracyclophane

A solution of 7-chloroformyl-4,12-dibromo[2.2]paracyclophane (6 mmol) in CH₂Cl₂ (12 mL) was treated with tert-butyl alcohol, tBuOH (12 mL) and stirred overnight at 50°C. After cooling down

to room temperature and diluting with MTBE (25 mL), the organic phase was washed with 2.8 M NH₄Cl, H₂O and saturated aqueous NaHCO₃, dried over MgSO₄ and concentrated under vacuum to afford the product (2.2 g, 79% yield) as a white solid (mp = 128.5 °C). ¹H NMR (CDCl₃): 1.56 (s, 9H, tBu), 2.7-2.8 (m, 1H), 2.8-3.0 (m, 4H), 3.2-3.4 (m, 2H), 3.7-3.8 (m, 1H), 5 6.38 (dd, 1H, J = 7.8, 1.8 Hz), 6.47 (d, 1H, J = 7.8 Hz), 7.05 (s, 1H), 7.08 (d, 1H, J = 1.8 Hz), 7.13 (s, 1H) ppm. ¹³C NMR (CDCl₃): 27.7 (q, 3x, tBu), 31.6 (t), 32.3 (t), 34.8 (t), 35.1 (t), 80.7 (s), 126.0 (s), 129.9 (s), 130.6 (d), 131.7 (s), 132.2 (d), 132.7 (d), 134.5 (d), 136.5 (d), 138.4 (s), 138.5 (s), 141.5 (s), 142.8 (s), 165.2 (s, CO) ppm.

10 d) Preparation of 7-carboxy-4,12-dibromo[2.2]paracyclophane from acyl chloride




A solution of 7-chloroformyl-4,12-dibromo[2.2]paracyclophane (1 mmol) in tetrahydrofuran, THF (2 mL) was treated with H₂O (1 mL) and stirred overnight at room temperature. The reaction mixture was then diluted with MTBE and washed with brine and H₂O. The organic phase was 15 then dried (an MgSO₄) and concentrated under vacuum, the obtained solid was re-crystallised from hot MTBE/hexane to afford the product (328 mg, 80% yield) as a white solid (mp = 239.7 °C). ¹H NMR (CDCl₃): 2.7-2.8 (m, 1H), 2.9-3.0 (m, 4H), 3.2-3.4 (m, 2H), 3.8-3.9 (m, 1H), 6.42 (d, 1H, J = 7.8 Hz), 6.52 (d, 1H, J = 7.8 Hz), 7.10 (s, 1H), 7.17 (s, 1H), 7.18 (s, 1H) ppm. ¹³C NMR (CDCl₃): 31.6 (t), 32.2 (t), 32.8 (t), 35.4 (t), 126.7 (s), 129.2 (s), 131.2 (d), 132.3 (s), 20 132.8 (d), 133.4 (d), 135.4 (d), 137.6 (d), 139.2 (s), 139.5 (s), 141.1 (s), 145.1 (s), 171.6 (s, CO) ppm. (S)-7-carboxy-4,12-dibromo[2.2]paracyclophane: [α]_D = + 217.5 (CH₂Cl₂, c = 16.4 mg/mL).

e) Preparation of 7-carboxy-4,12-dibromo[2.2]paracyclophane from ester

25 4,12-dibromo-7-methoxycarbonyl [2.2]paracyclophane (4.3 g, 10.14 mmol) was refluxed for 16 hours in MeOH/H₂O in presence of an excess of lithium hydroxide, LiOH. The crude product so obtained was purified by washing the crude material with diethylether/hexane to give 3.40 g (82 % yield) of 7-carboxy-4,12-dibromo[2.2]paracyclophane.

30 f) Preparation of 7-carboxy-4,12-dibromo[2.2]paracyclophane [(S)-1-phenylethyl]amide from acyl chloride



A solution of 7-chloroformyl-4,12-dibromo[2.2]paracyclophane (2 mmol) in dichloromethane (10 mL) was treated with (S)-(-)- α -methylbenzylamine (5 mmol) and stirred at room temperature for 1 h. The reaction was then treated with 2.8 M NH₄Cl and extracted with dichloromethane. The combined organic phases were washed with H₂O and saturated aqueous NaHCO₃, dried over anhydrous MgSO₄ and concentrated under vacuum to afford 715 mg (70% yield) of a 1:1 mixture of (R)-7-carboxy-4,12-dibromo[2.2]paracyclophane [(S)-1-phenylethyl]amide and (S)-7-carboxy-4,12-dibromo[2.2]paracyclophane [(S)-1-phenylethyl]amide. Both diastereoisomers were separated by chromatographic column (SiO₂) from hexane/ethyl acetate 20:1 to hexane/ethyl acetate 3:1). 1st eluting isomer (315 mg, 31% yield): ¹H NMR (CDCl₃): 1.49 (d, 3H, J = 6.9 Hz, NHCH₂CH₃), 2.6-2.8 (m, 1H), 2.8-3.1 (m, 4H), 3.2-3.4 (m, 2H), 3.42 (dd, 1H, J = 12.4, 10.0 Hz), 5.19 (quint, 1H, J = 7.3 Hz, NHCH₂CH₃), 5.70 (d, 1H, J = 7.6 Hz, CONH), 6.32 (dd, 1H, J = 7.8, 1.6 Hz, Ar-H), 6.59 (s, 1H, Ar-H), 6.74 (d, 1H, J = 7.8 Hz, Ar-H), 7.11 (d, 1H, J = 1.6 Hz, Ar-H), 7.13 (s, 1H, Ar-H), 7.2-7.3 (m, 1H, Ph-H), 7.3-7.4 (m, 4H, Ph-H) ppm. 2nd eluting isomer (300 mg, 29% yield). ¹H NMR (CDCl₃): 7.4-7.3 (m, 4H, Ph-H), 7.3-7.2 (m, 1H, Ph-H), 7.10 (d, 1H, J = 1.7 Hz, Ar-H), 7.08 (s, 1H, Ar-H), 6.75 (d, 1H, J = 7.8 Hz, Ar-H), 6.64 (s, 1H, Ar-H), 6.36 (dd, 1H, J = 7.8, 1.7 Hz, Ar-H), 5.72 (d, 1H, J = 7.7 Hz, CONH), 5.18 (quint, 1H, J = 7.3 Hz, NHCH₂CH₃), 3.4-3.3 (m, 1H), 3.3-3.1 (m, 2H), 3.0-2.9 (m, 2H), 2.9-2.7 (m, 2H), 2.7-2.6 (m, 1H), 1.49 (d, 3H, J = 6.9 Hz, NHCH₂CH₃) ppm.

20

g) Resolution of racemic 7-carboxy-4,12-dibromo[2.2]paracyclophane

A suspension of racemic 7-carboxy-4,12-dibromo[2.2]paracyclophane (4.29 g, 10.5 mmol) in ethanol (EtOH, 30 mL) was treated with a solution of (-)-cinchonidine (3.08 mg, 10.5 mmol) in EtOH (30 mL), heated at 90°C for 1 h and stirred at room temperature for an additional 2 h.

25 The precipitated white crystalline solid (3.15 g, 4.5 mmol) was then filtered and identified as the cinchonidium salt of (S)-acid in 87% ee. The mother liquids contained 4.10 g of the cinchonidium salt of (R)-acid in 39% ee. The obtained solid was dissolved in EtOH (45 mL) at 90 °C and let stand over night at room temperature. Again, a white crystalline precipitate (1.9 g, 2.7 mmol) was formed and identified after filtration as the cinchonidium salt of (S)-acid in 97% ee (51% recovery of the (S)-acid enantiomer in 97% ee).

30 Diastereomeric mixture: ¹H NMR (CDCl₃): 1.65 (brs, 1H x 2), 1.8-2.0 (m, 3H x 2), 2.4-2.6 (m, 2H x 2), 2.7-3.1 (m, 6H x 2), 3.1-3.4 (m, 4H x 2), 3.92 (q, 1H x 2, J = 11.0 Hz), 4.19 (brs, 1H x 2), 4.89 (d, 1H x 2, J = 10.4 Hz), 4.94 (d, 1H x 2, J = 17.2 Hz), 5.51 (ddd, 1H x 2, J = 17.2, 10.4, 7.1 Hz), 6.15 (s, 1H x 2), 6.19 (d, 1H, J = 7.8 Hz, Ar-H), 6.32 (d, 1H, J = 7.8 Hz, Ar-H), 6.55 (d, 1H, J = 7.8 Hz, Ar-H), 6.56 (d, 1H, J = 7.8 Hz, Ar-H), 6.91 (s, 1H x 2, Ar-H), 6.95 (s, 1H, Ar-H), 6.99 (s, 1H, Ar-H), 7.04 (brs, 1H x 2, Ar-H), 7.30 (t, 1H x 2, J = 7.5, Ar-H), 7.5-7.6 (m, 2H x 2,

Ar-H), 7.89 (d, 1H x 2, J = 8.4 Hz, Ar-H), 8.00 (d, 1H x 2, J = 8.4 Hz, Ar-H), 8.79 (d, 1H x 2, J = 4.5 Hz, Ar-H) ppm.

Salt from (S)-enantiomer of the carboxylic acid: ^1H NMR (CDCl_3): 1.66 (brs, 1H), 1.9-2.1 (m, 3H), 2.2-2.3 (m, 1H), 2.50 (brs, 1H), 2.6-2.8 (m, 3H), 2.9-3.4 (m, 7H), 3.81 (t, 1H, J = 11.0 Hz),


- 5 4.23 (brs, 1H), 4.87 (d, 1H, J = 10.4 Hz), 4.92 (d, 1H, J = 17.2 Hz), 5.46 (ddd, 1H, J = 17.2, 10.4, 7.1 Hz), 6.00 (s, 1H), 6.24 (d, 1H, J = 7.5 Hz, Ar-H), 6.51 (d, 1H, J = 7.7 Hz, Ar-H), 6.79 (s, 1H, Ar-H), 6.80 (s, 1H, Ar-H), 6.98 (brs, 1H, Ar-H), 7.24 (t, 1H, J = 7.5, Ar-H), 7.5-7.6 (m, 2H, Ar-H), 7.85 (d, 1H, J = 8.4 Hz, Ar-H), 7.96 (d, 1H, J = 8.4 Hz, Ar-H), 8.74 (d, 1H, J = 4.3 Hz, Ar-H) ppm. ^{13}C NMR (CDCl_3): 18.7 (t), 25.0 (t), 27.3 (d), 32.1 (t), 33.1 (t), 35.0 (t), 35.5 (t), 37.8 (d), 43.2 (t), 54.2 (t), 59.8 (d), 66.7 (d, CHOH), 116.7 (t, CHCH_2), 118.7 (d), 122.5 (d), 124.8 (s), 126.4 (s), 126.9 (d), 128.3 (d), 129.3 (d), 130.1 (d), 131.2 (d), 132.4 (d), 133.4 (s), 134.1 (d), 136.1 (s), 137.0 (d), 137.8 (s), 138.3 (d), 139.2 (s), 140.9 (s), 142.6 (s), 147.2 (s), 147.7 (s), 149.8 (d), 174.0 (s, CO) ppm. $[\alpha]_D = +74.4$ (CH_2Cl_2 , c = 12.6 mg/mL).

15 h) Analytical method for enantiomeric excess determination

- A solution of 7-carboxy-4,12-dibromo[2.2]paracyclophane in CH_2Cl_2 was treated with a 2M solution of (trimethylsilyl)diazomethane in hexane to form 4,12-dibromo-7-methoxycarbonyl [2.2]paracyclophane *in situ*. After removal of the solvents under reduced pressure, the reaction mixture was filtered through a plug of silica and analysed by HPLC (column Chiralcel OJ, solvent hexane, flow rate 1.5 mL/min, retention times: (R)-7-carboxy-4,12-dibromo[2.2]paracyclophane 8.7 min, (S)-7-carboxy-4,12-dibromo[2.2]paracyclophane 12.4 min).

Example 4. Synthesis of hydroxymethyl [2.2]paracyclophane derivatives and their ethers

25 a) Preparation of (R)-4,12-dibromo-7-hydroxymethyl[2.2]paracyclophane, method 1.



- To a solution of (R)-4,12-dibromo-7-methoxycarbonyl [2.2]paracyclophane (424 mg, 1 mmol) in THF (5 mL) at 0 °C was slowly added LiAlH_4 (2mL, 1 M solution in THF, 2 mmol). The reaction mixture was stirred at 0°C for 30 min, let warm up to room temperature for an extra 30 min, 30 cooled down again to 0°C, and quenched by slow addition of a 10:1 mixture $\text{MeOH}/\text{H}_2\text{O}$ (5 mL). After warming up to room temperature, MgSO_4 was added to absorb the excess of H_2O , the mixture was then filtered to eliminate the aluminium and magnesium salts and concentrated under vacuum to afford the product (356 mg, 90% yield) as a white solid (mp = 118.4 °C). ^1H NMR (CDCl_3): 2.6-2.8 (m, 2H), 2.8-3.0 (m, 3H), 3.1-3.2 (m, 1H), 3.34 (q, 2H, J = 13.1 Hz), 4.31 (d, 1H, J = 13.0 Hz, CH_2OH), 4.58 (d, 1H, J = 13.0 Hz, CH_2OH), 6.35 (d, 1H, J = 7.8 Hz),

6.43 (s, 1H), 6.56 (d, 1H, $J = 7.8$ Hz), 7.10 (s, 1H), 7.14 (s, 1H) ppm. ^{13}C NMR (CDCl_3): 29.9 (t), 32.1 (t), 34.4 (t), 35.3 (t), 63.4 (t), 125.5 (s), 126.8 (s), 131.2 (d), 131.4 (d), 133.1 (d), 133.8 (d, 2C), 138.4 (s), 138.8 (s), 139.1 (s), 139.8 (s), 141.1 (s) ppm. (*R*)-4,12-dibromo-7-hydroxymethyl[2.2]paracyclophane: $[\alpha]_D = -139.7$ (CH_2Cl_2 , c = 9.95 mg/mL).

5


b) Preparation of 4,12-dibromo-7-hydroxymethyl[2.2]paracyclophane, method 2

Borane-dimethyl sulfide complex (solution 2M in THF, 7.5 mL, 15 mmol) was added dropwise at room temperature to a THF (15 mL) solution of 7-carboxy-4,12-dibromo[2.2]paracyclophane (1.78 g, 4.34 mmol) (CAUTION! Violent reaction!). The reaction was heated to 45°C for 30

10 minutes, then stirred at room temperature for 14 hours. The reaction was concentrated under reduced pressure to about 5 mL and CH_2Cl_2 (50 mL) was added. The organic phase is washed with HCl 2N (2 x 50 mL) and NaHCO_3 saturated solution (50 mL), then dried over an. Na_2SO_4 and evaporated. The product was re-dissolved in MTBE (50 mL), washed with brine (2 x 50 mL), then dried over Na_2SO_4 and evaporated to give the product as a colourless oil that

15 solidified upon standing overnight at room temperature (1.66 g, 96% yield). The reaction was repeated on various batches of racemic and enantiopure materials and achieved yields of 94-100%.

c) Preparation of 4,12-dibromo-7-(triisopropylsilyloxy)methyl[2.2]paracyclophane



20


Lutidine (0.97 mL, 8.4 mmol) was added to a dichloromethane (25 mL) solution of 4,12-dibromo-7-hydroxymethyl[2.2]paracyclophane (1.66 g, 4.19 mmol), then trisopropylsilyltriflate (1.21 mL, 4.5 mmol) was added dropwise over 5 minutes at room temperature. The reaction was stirred at room temperature for one hour, then the solvent was concentrated under

25 reduced pressure to about 5 mL and HCl 2N (50 mL) was added. The reaction was extracted with MTBE (2 x 50 mL). The combined organic layers were washed with brine (40 mL), dried over Na_2SO_4 and evaporated to give the product as a pale yellow oil that solidified upon standing at room temperature (1.95 g, 84% yield, mp = 96.8°C). ^1H NMR (CDCl_3): 1.05-0.95 (6 lines, 18H, CH- CH_3), 1.1 (m, 3H, Si-CH), 2.6-2.8 (m, 2H, CH_2), 2.8-2.9 (m, 2H, CH_2), 2.9-3.1

30 (m, 2H, CH_2), 3.3-3.4 (m, 2H, CH_2), 3.34 (q, 2H, $J = 15$ Hz, CH_2OH), 4.45 (d, 1H, $J = 15$ Hz, CH_2OH), 4.65 (d, 1H, $J = 13.0$ Hz, CH_2OH), 6.32 (d, 1H, $J = 8$ Hz), 6.56 (s, 1H), 6.64 (d, 1H, $J = 8$ Hz), 7.03 (s, 1H), 7.16 (s, 1H) ppm. ^{13}C NMR (CDCl_3): 12.0 (CH- CH_3), 18.0 (CH- CH_3), 29.8 (CH_2), 32.1 (CH_2), 34.2 (CH_2), 35.5 (CH_2), 63.2 (CH_2O), 124.6 (C), 126.7 (C), 131.31 (CH), 131.33 (CH), 132.7 (CH), 133.05 (CH), 133.2 (CH); 137.6 (C), 138.3 (C), 138.7 (C), 140.3 (C), 35 141.2 (C) ppm. (*S*)-4,12-dibromo-7-(triisopropylsilyloxy)methyl[2.2]paracyclophane: $[\alpha]_D =$

94.17 (CH_2Cl_2 , $c = 9.85 \text{ mg/mL}$). The reaction was repeated on different batches of racemic and enantiopure starting material (yields 82-94%).

d) Preparation of 4,12-dibromo-7-(triphenylmethoxy)methyl[2.2]paracyclophane



5

Method 1: A mixture of 4,12-dibromo-7-hydroxymethyl[2.2]paracyclophane (396 mg, 1 mmol), DMAP (12 mg, 0.1 mmol) and trityl bromide (388 mg, 1.2 mmol) in pyridine (5 mL) was stirred at room temperature for 48 hours. The reaction mixture was then diluted with MTBE, washed with 2.8M NH_4Cl , H_2O and saturated aqueous NaHCO_3 , dried (an MgSO_4) and concentrated under vacuum to afford a residue that was purified by flash chromatography (SiO_2 , 10% AcOEt in hexane) to yield the product (415 mg, 65% yield) as a white solid ($\text{mp} = 201.3^\circ\text{C}$).

10 Method 2: Trityl chloride (659 mg, 2.36 mmol) was added in one portion to a solution of 4,12-


15 dibromo-7-hydroxymethyl[2.2]paracyclophane (780 mg, 1.97 mmol) and DBU (0.4 mL, 2.76 mmol) in CH_2Cl_2 (7 mL) at room temperature. After stirring for 16 hours the reaction was

15 quenched by addition of 10% HCl (10 mL), extracted with CH_2Cl_2 , washed with saturated aqueous NaHCO_3 and saturated aqueous NaCl , dried (MgSO_4) and concentrated under vacuum to afford a residue that was purified by flash chromatography (hexane/ethyl acetate 20:1) to yield the product (1140 mg, 91% yield) as a white solid.

20 $^1\text{H NMR}$ (CDCl_3): 2.11 (dt, 1H, $J = 13.6, 8.4 \text{ Hz}$), 2.6-2.8 (m, 2H), 2.8-3.1 (m, 4H), 3.38 (dd, 1H, $J = 11.7, 11.2 \text{ Hz}$), 3.77 (d, 1H, $J = 12.2 \text{ Hz}$, CH_2OTr), 3.99 (d, 1H, $J = 12.2 \text{ Hz}$, CH_2OTr), 6.02 (d, 1H, $J = 7.8 \text{ Hz}$), 6.22 (d, 1H, $J = 7.8 \text{ Hz}$), 6.65 (s, 1H), 7.04 (s, 1H), 7.08 (s, 1H), 7.22 (d, 3H, $J = 8.0 \text{ Hz}$, OTr), 7.29 (t, 6H, $J = 8.0 \text{ Hz}$, OTr), 7.46 (d, 6H, $J = 8.0 \text{ Hz}$, OTr) ppm. $^{13}\text{C NMR}$ (CDCl_3): 29.9 (t), 32.1 (t), 33.9 (t), 35.4 (t), 63.7 (t), 86.9 (s), 124.9 (s), 126.7 (s), 127.2 (d, 3C,

25 (d), 138.1 (s), 138.2 (s), 138.7 (s), 138.8 (s), 141.0 (s), 143.8 (d, 3C, OTr) ppm. (S)-4,12-dibromo-7-(triphenylmethoxy)methyl[2.2]paracyclophane: $[\alpha]_D = 68.33$ (CH_2Cl_2 , $c = 6.09 \text{ mg/mL}$).

e) Preparation of (R)-4,12-dibromo-7-(1-hydroxy-1-methylethyl)[2.2]paracyclophane




30

To a solution of 4,12-dibromo-7-methoxycarbonyl [2.2]paracyclophane (424 mg, 1 mmol) in THF (5 mL) at -78°C was slowly added methylmagnesium bromide (3 mL, 1M solution in butyl

ether, 3 mmol). The reaction mixture was stirred at -78°C for 1 h, let warm up to room temperature for an extra hour, cooled down to 0 °C, and quenched by slow addition of HCl 2N (5 mL). The reaction was then extracted with MTBE (2 x 10 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and evaporated to give the product (424 mg, quantitative yield) as a white solid. ¹H NMR (CDCl₃): 1.37 (s, 3H, CH₃), 1.57 (s, 3H, CH₃), 2.6-2.7 (m, 1H), 2.8-3.1 (m, 4H), 3.2-3.4 (m, 2H), 3.5-3.6 (m, 1H), 6.29 (d, 1H, J = 7.9 Hz), 6.47 (s, 1H), 6.58 (d, 1H, J = 7.9 Hz), 6.98 (s, 1H), 7.26 (s, 1H) ppm.

Example 5. Synthesis of hydroxy[2.2]paracyclophane derivatives and their ethers

10 a) Preparation of (R)-4,12-dibromo-7-formyl[2.2]paracyclophane




Method 1. A solution of (R)- 4,12-dibromo[2.2]paracyclophane (848 mg, 2.3 mmol) in CH₂Cl₂ (16 mL) at 0°C was subsequently treated with TiCl₄ (4 mL, 1M solution in CH₂Cl₂, 4.0 mmol) and Cl₂CHOMe (1.9 mL, 2.1 mmol). After stirring at 0 °C for 1 hour and at room temperature 15 for 16 hours, the mixture was poured into ice and stirred for an additional hour. The reaction mixture was then extracted with CH₂Cl₂ and the combined organic phases were washed with saturated aqueous NaHCO₃ and brine, dried over Na₂SO₄ and evaporated. The obtained crude was then purified by column chromatography (hexane/ethyl acetate 10:1) to afford 763 mg of (R)-4,12-dibromo-7-formyl[2.2]paracyclophane (85% yield) as a white solid.

20 Method 2. Alternatively, over night treatment of (S)-4,12-dibromo-7-hydroxymethyl[2.2]paracyclophane (396 mg, 1.0 mmol) in CH₂Cl₂ (5 mL) with MnO₂ (869 mg, 10.0 mmol) afforded (S)-4,12-dibromo-7-formyl[2.2]paracyclophane (377 mg, 96% yield) after filtering the reaction mixture through celite and evaporating the solvents under reduced pressure (mp = 128.0°C). ¹H NMR (CDCl₃): 2.7-2.9 (m, 2H), 2.9-3.1 (m, 3H), 3.3-3.5 (m, 2H), 3.79 (dd, 1H, J = 13.0, 9.9 Hz), 6.33 (d, 1H, J = 7.8 Hz), 6.36 (dd, 1H, J = 7.8, 1.5 Hz), 6.95 (s, 1H), 7.08 (d, 1H, J = 1.5 Hz), 7.23 (s, 1H), 9.82 (s, 1H, CHO) ppm. ¹³C NMR (CDCl₃): 30.4(t), 32.2 (t), 35.3 (t), 35.7 (t), 126.8 (s), 131.0 (d), 132.8 (d), 133.0 (s), 133.9 (d), 135.3 (d), 136.1 (s), 137.8 (d), 138.7 (s), 140.0 (s), 141.1 (s), 144.1 (s), 190.9 (s, COH) ppm. [α]_D = -126.7 (CH₂Cl₂, c = 5.67 mg/mL).

30

b) Preparation of (R)-4,12-dibromo-7-hydroxy[2.2]paracyclophane



3-Chloroperbenzoic acid (501 mg, 75% max purity, 2.9 mmol) was added in portions to a solution of (*R*)-4,12-dibromo-7-formyl[2.2]paracyclophane (763 mg, 1.94 mmol) in CH₂Cl₂ (12 mL) at room temperature. After stirring overnight, the reaction mixture was cooled to 0°C and the precipitated 3-chlorobenzoic acid was filtered off. The organic solution was then washed with saturated aqueous NaHCO₃, dried over Na₂SO₄ and evaporated. The crude, identified as (*R*)-4,12-dibromo-7-formyloxy[2.2]paracyclophane, was dissolved in MeOH (12 mL), treated with a 2M solution of NaOH (5 mL) and stirred at room temperature for 30 minutes. Once the hydrolysis reaction is completed, the reaction mixture was extracted with MTBE, washed with 10% HCl and brine, dried over Na₂SO₄ and evaporated. The obtained crude was then purified by column chromatography (SiO₂, hexane/ethyl acetate 5:1) to afford 570 mg (*R*)-4,12-dibromo-7-hydroxy[2.2]paracyclophane in 75% yield as a white solid. ¹H NMR (CDCl₃): 2.57 (ddd, 1H, J = 13.1, 10.4, 6.4 Hz), 2.78 (ddd, 1H, J = 13.1, 9.8, 7.3 Hz), 2.8-3.1 (m, 4H), 3.2-3.3 (m, 2H), 4.58 (brs, 1H, OH), 5.62 (s, 1H), 6.38 (dd, 1H, J = 7.8, 1.4 Hz), 6.92 (d, 1H, J = 7.8 Hz), 7.06 (s, 2H) ppm. ¹³C NMR (CDCl₃): 28.3 (t), 32.4 (t), 33.9 (t), 35.2 (t), 117.3 (s), 123.6 (d), 127.2 (s), 127.4 (s), 130.7 (d), 130.9 (d), 133.7 (d), 134.1 (d), 139.0 (s), 140.4 (s), 140.7 (s), 153.9 (s) ppm. [α]_D = -101.2 (CH₂Cl₂, c = 9.9 mg/mL).


c) Preparation of (*R*)-4,12-dibromo-7-methoxy[2.2]paracyclophane



20 A solution of (*R*)-4,12-dibromo[2.2]paracyclophan-7-ol (563 mg, 1.47 mmol) in THF (5 mL) was slowly added to a suspension of NaH (65 mg, 60% in mineral oil, 1.62 mmol) in THF (10 mL) at room temperature. After stirring for 5 minutes, iodomethane (135 μL, 2.2 mmol) was slowly added under reduced pressure, the crude was dissolve in MTBE and washed with 10% NaOH, 10% HCl and brine, dried over Na₂SO₄ and evaporated. The crude was purified by column chromatography (SiO₂, hexane/ethyl acetate 20:1) to afford 514 mg of (*R*)-4,12-dibromo-7-methoxy[2.2]paracyclophane (88% yield) as a white solid (mp = 118.2 °C). ¹H NMR (CDCl₃): 2.66 (ddd, 1H, J = 13.2, 11.5, 6.2 Hz), 2.71 (ddd, 1H, J = 13.7, 9.7, 7.3 Hz), 2.8-3.0 (m, 2H), 2.99 (ddd, 1H, J = 13.0, 10.2, 6.2 Hz), 3.12 (dd, 1H, J = 12.7, 9.7 Hz), 3.20 (dd, 1H, J = 13.0, 10.2 Hz), 3.31 (ddd, 1H, J = 12.3, 10.2, 2.0 Hz), 3.62 (s, 3H, OCH₃), 5.70 (s, 1H), 6.37 (dd, 1H, J = 7.8, 1.7 Hz), 6.67 (d, 1H, J = 7.8 Hz), 7.03 (d, 1H, J = 1.7 Hz), 7.07 (s, 1H) ppm. ¹³C NMR (CDCl₃): 28.5 (t), 32.4 (t), 34.0 (t), 35.6 (t), 54.6 (q, OCH₃), 116.9 (s), 117.8 (d), 127.3 (s), 128.7 (s), 130.5 (d), 130.7 (d), 133.7 (d, 2C), 139.5 (s), 140.2 (s), 140.4 (s), 157.6 (s) ppm. [α]_D = -125.6 (CH₂Cl₂, c = 11.53 mg/mL).


Example 6. Synthesis of phosphine ligands based on [2.2]paracyclophane derivatives

- a) Preparation of (*R*)-4,12-bis(diphenylphosphino)-7-(triphenylmethoxy)methyl[2.2]paracyclophane ("TriOCH₂-ParaC")



5 To a solution of (*R*)-4,12-dibromo-7-(triphenylmethoxy)methyl[2.2]paracyclophane (638 mg, 1 mmol) in THF (5 mL) at -78°C was slowly added *t*-BuLi (2.5 mL, 1.7 M in pentane, 4.2 mmol) and the coloured mixture was stirred at this temperature for 30 minutes. The cooling bath was then removed and a mixture of chlorodiphenylphosphine (0.5 mL, 2.2 mmol) in THF (3 mL) was added drop-wise. The yellow solution was stirred for 1 hour, treated with SiO₂ and stirred for 10 an extra 30 min. The SiO₂ was filtered off and washed with CH₂Cl₂. The solvents were removed under vacuum and the residue was dissolved in CH₂Cl₂, filtered to eliminate the LiCl formed during the reaction and triturated by addition of hexane. After stirring the mixture for 1 hour, the precipitated product was collected by filtration (680 mg, 80% yield). ¹H NMR (CDCl₃): 7.5-7.0 (m, 35H, OTr + PPh₂), 6.70 (d, 1H, J = 5.3 Hz), 6.55 (d, 1H, J = 9.0 Hz), 6.42 (d, 1H, J = 9.0 Hz), 6.29 (d, 1H, J = 7.7 Hz), 6.08 (dd, 1H, J = 7.7, 5.3 Hz), 4.06 (d, 1H, J = 12.2 Hz, CH₂OTr), 3.90 (d, 1H, J = 12.2 Hz, CH₂OTr), 3.0-2.5 (m, 7H), 2.0-1.9 (m, 1H) ppm. ³¹P NMR (CDCl₃): -1.18, -1.24 ppm.

- b) Preparation of *rac*-4,12-bis(diphenylphosphino)-7-(triisopropylsilyloxy)-methyl[2.2]paracyclophane ("TIPSO-CH₂-ParaC")




20 To a diethyl ether (17 mL) solution of 4,12-dibromo-7-(triisopropylsilyloxy)methyl[2.2]paracyclophane (555 mg, 1 mmol) at -78°C was slowly added *t*-BuLi (2.35 mL, 1.7M in pentane, 4 mmol) and the coloured solution was stirred at -78°C for one hour. The reaction was quenched by adding chlorodiphenylphosphine (0.45 mL, 2.5 mmol) at -78°C. The colour 25 immediately changed from orange to pale yellow. The cooling bath was removed, the reaction stirred at room temperature for 30 minutes and a white solid (LiCl) precipitated. The reaction was treated with SiO₂, stirred for further 30 minutes and then filtered under nitrogen. The solution was evaporated to give a pale yellow solid that was deemed to be of sufficient purity 30 (750 mg, quantitative yield). ³¹P NMR (CDCl₃): -1.2, -1.7 ppm.

c) Preparation of (*R*)-4,12-bis(diphenylphosphino)-7-(tris-isopropylsilyloxy) methyl-[2.2]paracyclophane ("TIPSO-CH₂-ParaC")

To a diethyl ether (20 mL) solution of (*R*)-4,12-dibromo-7-(tris-isopropylsilyloxy) methyl-[2.2]paracyclophane (556 mg, 1 mmol) at -78°C was slowly added *t*-BuLi (2.4 mL, 1.7 M in pentane, 4.05 mmol) and the coloured solution was stirred at -78°C for 40 minutes. The reaction was quenched by adding chlorodiphenylphosphine (0.45 mL, 2.5 mmol) at -78°C. The colour immediately changed from orange to pale yellow. The cooling bath was removed, the reaction stirred at room temperature for 100 minutes and a white solid (LiCl) precipitated. The reaction was treated with SiO₂, stirred for one hour and then filtered under nitrogen. The solution was evaporated and the solid residue was washed with methanol (5 mL) and diethyl ether (5 mL). After further washing with methanol (5 mL) the resulting white solid (mp = 170.6°C) was dried under vacuum (420 mg, 55% yield). ¹H NMR (CDCl₃): 1.0-1.15 (m, 21H, TIPS-O), 2.4-2.6 (m, 2H, CH₂), 2.8-3.0 (m, 6H, CH₂), 4.6 (d, 1H, J = 15 Hz, CH₂-O), 4.7 (d, 1H, J = 15 Hz, CH₂-O), 6.35-6.45 (4 lines, 2H, H arom), 6.55-6.65 (m, 3H, H arom), 7.05-7.50 (m, 20H, H arom). ³¹P NMR (CDCl₃): -1.2, -1.7 ppm. [α]_D = -25.5 (CH₂Cl₂, c = 10.57 mg/mL).


d) Preparation of (*S*)-4,12-bis[bis(3,5dimethylphenyl)phosphino]-7-(tris-isopropylsilyloxy) methyl-[2.2]paracyclophane ("TIPSO-CH₂-Xyl-ParaC")



To a diethyl ether (20 mL) solution of (*S*)-4,12-dibromo-7-(tris-isopropylsilyloxy)methyl-[2.2]paracyclophane (276 mg, 0.5 mmol) at -78°C was slowly added *t*-BuLi (1.23 mL, 1.7 M in pentane, 2.1 mmol) and the coloured solution was stirred at -78°C for 45 minutes. The reaction was quenched by adding a diethyl ether (6 mL) solution chloro-bis-(3,5-dimethylphenyl)phosphine (0.33 g, 1.2 mmol) at -78°C. The cooling bath was removed, the reaction stirred at room temperature for one hour and a white solid (LiCl) precipitated. The reaction was treated with SiO₂, stirred for one hour and then filtered under nitrogen. The solvent was evaporated, the solid residue was re-dissolved in 10 mL of toluene/hexane 2/3 and eluted through a 2 cm silica gel plug. The solvent was removed under vacuum to give the product as a white solid (110 mg, 25% yield, mp = 160.1°C). ¹H NMR (CDCl₃): 1.0-1.10 (m, 21H, TIPS-O), 2.1 (s, 12H, 4 CH₃), 2.2 (s, 6H, 2 CH₃), 2.25 (s, 3H, CH₃), 2.27 (s, 3H, CH₃), 2.35-2.55 (m, 2H, CH₂), 2.7-2.9 (m, 6H, CH₂), 4.55 (d, 1H, J = 14 Hz, CH₂-O), 4.7 (d, 1H, J = 14

Hz, CH₂-O), 6.30 (dd, 1H, H arom), 6.47 (4 lines, 2H, H arom), 6.59 (m, 2H, H arom), 6.7-7.2 (m, 12H, H arom). ³¹P NMR (CDCl₃): 0.3, -0.3 ppm.

e) Preparation of (S)-4,12-bis[bis(3,5-dimethyl-4-methoxyphenyl)phosphino]-7-(tris-isopropylsilyloxy) methyl[2.2]paracyclophane ("TIPSO-CH₂-MeOXyl-ParaC")




5

To a diethyl ether (15 mL) solution of (S)-4,12-dibromo-7-(tris-isopropylsilyloxy)methyl[2.2]paracyclophane (185 mg, 0.34 mmol) at -78 °C was slowly added *t*-BuLi (0.82 mL, 1.7 M in pentane, 1.4 mmol) and the coloured solution was stirred at -78°C for 45 minutes. The solution containing the dianion was added dropwise to a diethyl ether (8 mL) solution chloro-
10 bis-(3,5-dimethyl-4-methoxyphenyl)phosphine (0.24 g, 0.72 mmol) at room temperature. The reaction was stirred at room temperature for two hours and a white solid (LiCl) precipitated. The reaction was treated with SiO₂, stirred for three hours and then filtered under nitrogen. The solvent was evaporated and the crude product was used without any further purification (see below, example h). ³¹P NMR (CDCl₃): -2, -3 ppm.

15

f) Preparation of *rac*-4,12-bis(diphenylphosphino)-7-hydroxymethyl[2.2]paracyclophane ("HO-CH₂-ParaC")




20

Tetrabutylammonium fluoride (1.2 mL, 1 M solution in THF + 5% water) was added to a THF 15 mL solution of *rac*-4,12-bis(diphenylphosphino)-7-(triphenylmethoxy)-methyl[2.2]paracyclophane (866 mg, 1.14 mmol) and the reaction was stirred at room temperature for one hour. The solvent was evaporated and degassed diethyl ether (50 mL) was added. The ether solution was washed with water (50 mL), HCl 2N (50 mL) and NaHCO₃ sat solution (50 mL), then dried over Na₂SO₄, filtered under nitrogen and evaporated. The resulting pale yellow solid
25 residue was washed with diethyl ether (1 mL) and hexane (5 mL) and dried to give the product as a off white solid (410 mg, 60% yield).

g) Preparation of (*R*)-4,12-bis(diphenylphosphino)-7-hydroxymethyl[2.2]paracyclophane ("HO-CH₂-ParaC")

Tetrabutylammonium fluoride (1.0 mL, 1 M solution in THF + 5% water, 1 mmol) was added to a THF (10 mL) solution of (*R*)-4,12-bis(diphenylphosphino)-7-(triphenylmethoxy)methyl[2.2]paracyclophane (650 mg, 0.85 mmol) and the reaction was stirred at room temperature for two hours. The solvent was evaporated and diethyl ether (50 mL) was added. The ether solution was washed with water (20 mL), HCl 2N (20 mL) and NaHCO₃ sat solution (20 mL), then dried over Na₂SO₄, filtered under nitrogen and evaporated. The resulting pale yellow solid residue was washed with pentane (2 x 10 mL) and dried to give the product as a off white solid (450 mg, 70% yield). ¹H NMR (CDCl₃): 2.4-2.5 (m, 2H, CH₂), 2.7-3.0 (m, 6H, CH₂), 4.32 (d, 1H, J= 14 Hz, CH₂-O), 4.6 (d, 1H, J= 14 Hz, CH₂-O), 6.30-6.35 (m, 2H, H arom), 6.4-6.5 (m, 3H H arom), 7.0-7.4 (m, 20H, H arom). ³¹P NMR (CDCl₃): -1.1, -1.3 ppm.


h) Preparation of (S)-4,12-bis[bis(3,5-dimethyl-4-methoxyphenyl)phosphino]hydroxymethyl [2.2]paracyclophane ("HO-CH₂-MeOXy[ParaC"])



15

A tetrahydrofuran solution of tetrabutyl ammonium fluoride (0.4 mL, 1 M solution, 0.4 mmol) was added to a THF (10 mL) solution of the crude product obtained in example g). The reaction was stirred at room temperature for two hours, then the solvent was evaporated. The solid residue was taken up in diethyl ether (20 mL) and, under inert atmosphere, washed with NaHCO₃ sat solution (10 mL) and HCl 2N (10 mL). The organic solution was dried over Na₂SO₄, filtered and evaporated. The crude product was purified by filtration over silica gel under inert atmosphere (eluent: toluene/diethyl ether 8/2). (75 mg, 29% yield + some impure fractions). ³¹P NMR (CDCl₃): -2.1, -2.4 ppm.


i) Preparation of *rac*-4,12-bis(diphenylphosphino)-7-tertbutoxycarbonyl[2.2]paracyclophane ("t-BuOOC-ParaC")



To a diethyl ether (20 mL) solution of *rac*-4,12-dibromo-7-tertbutoxycarbonyl [2.2]paracyclophane (358 mg, 0.77 mmol) at -78°C was slowly added t-BuLi (1.85 mL, 1.7 M in pentane, 3.151 mmol) and the coloured solution was stirred at -78°C for 40 minutes. The reaction was quenched by adding chloro-diphenylphosphine (0.3 mL, 1.7 mmol) at -78°C. The cooling bath was removed, the reaction stirred at room temperature for one hour and a white solid (LiCl) precipitated. The reaction was quenched with wet tetrahydrofuran (2 mL), diluted with more diethyl ether (20 mL) dried over Na₂SO₄ and filtered. The solvent was evaporated, the solid residue was washed with methanol (2 x 5 mL) and then dried under vacuum (320 mg, 47% yield). ¹H NMR (CDCl₃): 1.5 (s, 9H, t-Bu-O), 2.55 (m, 1H, CH₂), 2.63 (m, 1H, CH₂), 2.8-3.0 (m, 5H, CH₂), 3.7 (m, 1H, CH₂), 6.4-6.55 (m, 3H, H arom), 7.05-7.55 (m, 22H H arom). ³¹P NMR (CDCl₃): -1.35 ppm.

15

j) Preparation of *rac*-4,12-bis(diphenylphosphino)-7-methoxy[2.2]paracyclophane ("MeO-Para-C")




To a diethyl ether (15 mL) solution of *rac*-4,12-dibromo-7-methoxy [2.2]paracyclophane (133 mg, 0.335 mmol) at -78°C was slowly added t-BuLi (0.8 mL, 1.7 M in pentane, 1.36 mmol) and the coloured solution was stirred at -78°C for 90 minutes. The reaction was quenched by adding a diethyl ether (5 mL) solution chloro-diphenylphosphine (0.155 g, 0.7 mmol) at -78°C. The cooling bath was removed, the reaction stirred at room temperature for one hour and a white solid (LiCl) precipitated. The reaction was treated with SiO₂, stirred for one hour and then filtered under nitrogen. The solvent was evaporated, the solid residue was re-dissolved in 10 mL of toluene and eluted through a 2 cm silica gel plug. The solvent was removed under vacuum to give the product as a white solid of mp = 173.3°C (80 mg, 40% yield). ¹H NMR (CDCl₃): 2.4-2.5 (m, 1H, CH₂), 2.7-2.85 (m, 4H, CH₂), 2.9-3.05 (m, 3H, CH₂), 3.69 (s, 3H, OCH₃), 5.78 (d, 1H, J = 4.2 Hz, H arom), 6.42 (dd, 1H, J = 7.7, 1.5 Hz, H arom), 6.4-6.5 (m, 2H, H arom), 6.65 (dd, 1H, J = 7.7, 5.5 Hz H arom), 7.05-7.5 (m, 20H, H arom). ³¹P NMR (CDCl₃): -0.9, -3.0 ppm.

k) Preparation of (*R*)-4,12-bis(diphenylphosphino)-7-methoxy[2.2]paracyclophane ("MeO-ParaC")

To a diethyl ether (15 mL) solution of (*R*)-4,12-dibromo-7-methoxy [2.2]paracyclophane (100 mg, 0.25 mmol) at -78°C was slowly added *t*-BuLi (0.61 mL, 1.7 M in pentane, 1.0 mmol) and the coloured solution was stirred at -78°C for 50 minutes. The reaction was quenched by adding a diethyl ether (5 mL) solution of chloro-diphenylphosphine (0.125 g, 0.55 mmol) at -78°C. The cooling bath was removed, the reaction stirred at room temperature for one hour and a white solid (LiCl) precipitated. The reaction was treated with SiO₂, stirred for one hour and then filtered under nitrogen. The solvent was evaporated, the solid residue was dissolved in dichloromethane (1 mL) and hexane (3 mL). Dichloromethane was removed under vaccum, the resulting solid precipitate was allowed to settle and the supernatant was removed. The procedure was repeated twice. The product was isolated as a white powder (63 mg, 41% yield). $[\alpha]_D = 49.2$ (CH₂Cl₂, c = 1.16 mg/mL).

15


l) Preparation of *rac*-4,12-bis(diphenylphosphino)-7-*t*-butyldimethylsilyloxy[2.2]paracyclophane ("TBSO-ParaC")



To a diethyl ether (10 mL) solution of *rac*-4,12-dibromo-7-*t*-butyldimethylsilyloxy [2.2]paracyclophane (90 mg, 0.18 mmol) at -78°C was slowly added *t*-BuLi (0.44 mL, 1.7 M in pentane, 0.75 mmol) and the coloured solution was stirred at -78°C for 50 minutes. The reaction was quenched by adding a diethyl ether (5 mL) solution chloro-diphenylphosphine (0.125 g, 0.55 mmol) at -78°C. The cooling bath was removed, the reaction stirred at room temperature for one hour and a white solid (LiCl) precipitated. The reaction was treated with SiO₂, stirred for one hour and then filtered under nitrogen. The solvent was evaporated, the product was obtained as a white solid (85 mg, 67% yield). ¹H NMR (CDCl₃): 1.0 (s, 9H, *t*-BuSi), 1.08 (s, 3H, CH₃Si), 1.10 (s, 3H, CH₃Si), 2.4 (m, 1H, CH₂), 2.7-3.0 (m, 7H, CH₂), 5.70 (d, 1H, H arom), 6.4 (m, 2H, h arom), 6.5 (d, 1H, H arom), 6.9 (dd, 1H, H arom), 7.05-7.5 (m, 20H, H arom). ³¹P NMR (CDCl₃): -1.0, -2.35 ppm.

30


m) Preparation of 4,12-bis(diphenylphosphinooxide)-7-(trisopropylsilyloxy)methyl[2.2]para-cyclophane



Pd(OAc)₂ (31 mg, 0.14 mmol), bis-diphenylphosphinobutane (60 mg, 0.14 mmol) and diphenylphosphine-oxide (200 mg, 1 mmol) were dissolved in anhydrous, degassed DMSO (2 mL) and the reaction heated to 115°C. After 5 minutes 4,12-dibromo-7-(tris-isopropylsilyloxy)methyl[2.2]paracyclophane (200 mg, 0.36 mmol) was added and the reaction was stirred at 115°C for 16 hours. The solvent was evaporated, HCl 2N (50 mL) was added and the reaction was extracted with dichloromethane (3 x 50 mL). The combined organic layers were dried over Na₂SO₄, filtered and evaporated. The crude mixture was purified by chromatography (SiO₂, eluent: hexane/MTBE/dichloromethane 4/4/2) to give the product as a white powder (116 mg, 15% yield). ¹H NMR (CDCl₃): 1.05 (t, 9 H, CH₃-CH-Si, J = 8.5 Hz), 1.15 (m, 3H, CH₃CHSi), 2.65 (m, 2H, -CH₂-), 2.9 (m, 2H, -CH₂-), 3.1 (m, 2H, -CH₂-), 3.3 (m, 2H, -CH₂-), 4.65 (d, 1H, -CH₂-O, J = 6 Hz), 4.72 (d, 1H, -CH₂-O, J = 6 Hz), 6.53 (d, 1H, H arom), 6.2 (d, 1H, H arom), 6.25 (m, 1H, H arom), 6.95 (d, 1H, H arom), 7.12 (d, 1H, H arom), 7.2 (m, 3H, H arom), 7.28 (m, 2H, H arom), 7.45 (m, 11H, H arom), 7.6 (m, 4H, H arom). ³¹P NMR (CDCl₃): 23.3, 22.9 ppm. This material can be reduced to the corresponding phosphine by treatment with HSiCl₃, Et₃N in xylene at 120°C. NMR scale experiment: ³¹P NMR (CDCl₃): -1.2, -1.7 ppm.

20 Example 7. Synthesis of ruthenium complexes of phosphine ligands based on substituted [2.2]paracyclophane derivatives

a) Preparation of [(R)-TriOCH₂-Para-C]RuCl₂[(S,S)-Dpen]



The phosphine of Example 6a ((R) enantiomer, 50 mg, 0.05889 mmol) and [Ru(benzene)Cl]₂ (14.7 mg, 0.0294 mmol) were placed in a Schlenk flask and the air was replaced with nitrogen. Anhydrous, degassed DMF (1.5 ml) and toluene (2 ml) were added. The mixture was then heated at 105°C for 4 hours. A red homogeneous solution was obtained. To the solution was then added solid (S,S)-Dpen (12.5 mg, 0.05889 mmol) and the solution heated again for 1.75 hrs at 105°C. The solvent was then removed. The solid was dissolved in CH₂Cl₂ and MTBE added. Removal of the solvent caused precipitation of a tan coloured solid. The solid was not collected but the solvent completely removed to give the crude complex, which was used

without any further purification. ^{31}P NMR (CDCl_3): 43.98 ppm.

b) Preparation of [(S)-MeO-Para-C]RuCl₂[(R,R)-Dpen]

The (S) enantiomer of the phosphine prepared in Example 6j, 49 mg, 0.0807 mmol) and

- 5 [Ru(benzene)Cl]₂ (20.2 mg, 0.0403 mmol) were placed in a Schlenk flask and the air was replaced with nitrogen. Anhydrous, degassed DMF (1 ml) and toluene (1 ml) were added. The mixture was then heated at 105°C for 4 hours. To the solution was then added solid (S,S)-Dpen (17 mg, 0.0807 mmol) and the colour changed immediately from brown to yellow-beige. The reaction was allowed to cool to room temperature and the solvent was removed under vacuum.
- 10 The crude complex was used without any further purification. ^{31}P NMR (CDCl_3): 46.2 (d, $J=28$ Hz), 45.9 (d, 27.5 Hz) ppm.

c) Preparation of [(R)-TIPSOCH₂-Para-C]RuCl₂[(S,S)-Dpen]

The same procedure as used for example 7b was followed using the (R) enantiomer ligand of

- 15 example 6c. The crude complex was used without any further purification. ^{31}P NMR (CDCl_3): 43.6, 43.75, 43.8, 44.0 (not first order) ppm.

d) Preparation of [(R)-HOCH₂-Para-C]RuCl₂[(S,S)-Dpen]


The same procedure as used for example 7b was followed using the (R) enantiomer ligand of

- 20 example 6g. The crude complex was used without any further purification. ^{31}P NMR (CDCl_3): 44.0 (s) ppm .

Example 8. Synthesis of rhodium complexes of phosphine ligands based on

[2.2]paracyclophane derivatives

25 a) Preparation of [(R)-TriOCH₂-ParaC Rh NBD]BF₄




The phosphine of Example 6a ((R) enantiomer, 66 mg, 0.078 mmol) and [Rh(NBD)]₂BF₄ (27 mg, 0.072 mmol) (NBD = norbornadiene) were placed in Schlenk flask under inert nitrogen atmosphere and degassed dichloromethane (2 mL) was added at room temperature. The

- 30 colour of the solution quickly turned from red to orange. After one hour the solvent was removed under vacuum and the crude solid residue was washed with Et₂O (1 mL) and hexane (2 mL). The yellow suspension was stirred for one hour, then the solid was allowed to settle and the supernatant liquid was removed. The solid was washed with more hexane and dried under vacuum (50 mg, 63 % yield). The precatalyst was used without any further purification.

³¹P NMR (CDCl₃): 35.3 (dd, J_{P-Rh} = 158 Hz, ³J_{P-P} = 21 Hz), 37.4 (dd, J_{P-Rh} = 159 Hz, ³J_{P-P} = 21 Hz).

b) Preparation of [HO-CH₂-ParaC Rh NBD]BF₄



5

The (R)-enantiomer of the phosphine ligand of Example 6g (135 mg, 0.22 mmol) and [Rh(NBD)₂]BF₄ (75 mg, 0.2 mmol) (NBD = norbornadiene) were placed in Schlenk flask under inert nitrogen atmosphere and degassed CH₂Cl₂ (15 mL) was added at room temperature. The colour of the solution quickly turned from red to orange. After two hours the solvent was

10 removed under vacuum and the crude solid residue was washed with diethyl ether (1 mL) and hexane (5 mL). The solid was allowed to settle and the supernatant liquid was removed and the solid dried under vacuum (145 mg, 81% yield). ³¹P NMR (CDCl₃): 35.2 (dd, J_{P-Rh} = 158 Hz, ³J_{P-P} = 21 Hz), 36.4 (dd, J_{P-Rh} = 160 Hz, ³J_{P-P} = 20 Hz).


15

c) Preparation of rhodium complexes: general procedure

The phosphine ligand and an equimolar amount of [Rh(NBD)₂] were placed in Schlenk flask under inert nitrogen atmosphere and dichloromethane was added at room temperature. The colour of the solution in each case quickly turned from red to orange. After 0.5-2 hours the solvent was removed under vacuum and the crude solid residue was analysed by ³¹P NMR.

20 The product may be used without any further purification or if desired may be purified by washing with diethyl ether and hexane.

- (i) [(S)-TIPSO-CH₂-Xyl-Para-C Rh NBD]BF₄ (yield not calculated). ³¹P NMR (CDCl₃): 36.2 (dd, J_{P-Rh} = 159 Hz, ³J_{P-P} = 21 Hz), 37.1 (dd, J_{P-Rh} = 159 Hz, ³J_{P-P} = 21 Hz).
- (ii) [(S)-HO-CH₂-MeOXyl-Para-C Rh NBD]BF₄ (yield not calculated). ³¹P NMR (CDCl₃): 34.0 (dd, J_{P-Rh} = 159 Hz, ³J_{P-P} = 21 Hz), 36.0 (dd, J_{P-Rh} = 159 Hz, ³J_{P-P} = 21 Hz).
- 25 (iii) [rac-tBuOOOC-Para-C Rh NBD]BF₄ (yield not calculated). ³¹P NMR (CDCl₃): 35.9 (dd, J_{P-Rh} = 159 Hz, ³J_{P-P} = 23 Hz), 37.8 (dd, J_{P-Rh} = 159 Hz, ³J_{P-P} = 23 Hz).
- (iv) [rac-CH₃O-Para-C Rh NBD]BF₄ (83% yield) and [(R)-CH₃O-ParaC Rh NBD]BF₄ (yield not calculated). ³¹P NMR (CDCl₃): 34.1 (dd, J_{P-Rh} = 157 Hz, ³J_{P-P} = 21 Hz), 38.1 (dd, J_{P-Rh} = 157 Hz, ³J_{P-P} = 20 Hz).
- 30 (v) [rac-TBSO-Para-C Rh NBD]BF₄ (98% yield). ³¹P NMR (CDCl₃): 34.9 (dd, J_{P-Rh} = 159 Hz, ³J_{P-P} = 21 Hz), 37.9 (dd, J_{P-Rh} = 160 Hz, ³J_{P-P} = 21 Hz).

Example 9. Hydrogenation of aromatic ketonesa) Hydrogenation of acetophenone at S/C 3000/1 in Parr autoclave

In a 50 mL glass-liner was added [(R)-TriOCH₂-ParaC]-RuCl₂[(S,S)-Dpen] (0.002 mmol). This

5 was placed in the Parr autoclave and the air replaced with nitrogen. A solution of acetophenone (6 mmol) and *t*-BuOK in 2-propanol was then added to the Parr autoclave. The Autoclave was then pressurised with hydrogen to 8.3 bar and left to stir at room temperature. After 30 minutes the uptake of hydrogen had stopped. The autoclave was opened and the solution analysed by gas-chromatography (column: Chirasil DEX-CB, method: 100°C for 7

10 minutes, then 15°C to 200°C): >99 % conversion, 98 % e.e.

b) Hydrogenation of acetophenone at S/C 5000/1 in Argonaut Endeavour

[(R)-TriOCH₂-ParaC]-RuCl₂[(S,S)-Dpen] (1 mg, 0.001 mmol) was placed in a glass liner in an Endeavour Argonaut multi-well pressure reactor. The vessel was purged with nitrogen and a

15 solution of acetophenone (5 mmol) in 2-propanol (2 mL) was added. A solution of *t*-BuOK (0.1 mmol, B/C 100/1, 2% with respect to acetophenone) in 2-propanol (2 mL) was added, the reaction was purged with nitrogen and pressurised to 10 bar hydrogen. The pressure was maintained at 10 bar and the hydrogen uptake monitored. The reaction was complete in 40 minutes. The pressure was released and the reaction analysed by chiral gas-chromatography:

20 > 99 % conversion, 98.5 % e.e.

In a 50 mL glass-liner was added [(R)-TriOCH₂-ParaC]-RuCl₂[(S,S)-Dpen] (0.001 mmol). This was placed in the Parr autoclave and the air replaced with nitrogen. A solution of

25 acetophenone (10 mmol) and *t*-BuOK in 2-propanol (0.4 mmol, B/C 400, 4 % with respect to acetophenone) was then added to the Parr autoclave. The Autoclave was then pressurised with hydrogen to 10 bar and left to stir at room temperature. Upon completion of the reaction, the autoclave was opened and the solution analysed by gas-chromatography (column: Chirasil DEX-CB, method: 100°C for 7 minutes, then 15°C to 200°C): >99 % conversion, 99 % e.e.


30

The results for a series of catalysts are given below;

Catalyst	S/C	Approx. time to completion	Conv. (%)	e.e. (%)
[(R)-TriOCH ₂ -Para-C]-RuCl ₂ -[(S,S)-Dpen]	3000/1	30 min	> 99	98 (R)
[(S)-MeO-Para-C]-RuCl ₂ -[(R,R)-Dpen]	3000/1	30 min	> 99	98 (S)
[(R)-TriOCH ₂ -Para-C]-RuCl ₂ -[(S,S)-Dpen]	5000/1	40 min	> 99	98.5 (R)
[(R)-TIPSOCH ₂ -Para-C]-RuCl ₂ -[(S,S)-Dpen]	5000/1	15 min	> 99	98.3 (R)
[(R)-HOCH ₂ -Para-C]-RuCl ₂ -[(S,S)-Dpen]	5000/1	30 min	> 99	97.9 (R)
[(R)-TriOCH ₂ -Para-C]-RuCl ₂ -[(S,S)-Dpen]	10000/1	30 min	> 99	99.2 (R)
[(R)-TIPSOCH ₂ -Para-C]-RuCl ₂ -[(S,S)-Dpen]	10000/1	1 hour	> 99	98.5 (R)
[(R)-HOCH ₂ -Para-C]-RuCl ₂ -[(S,S)-Dpen]	10000/1	40 min	> 99	99.3 (R)
[(S)-MeO-Para-C]-RuCl ₂ -[(S,S)-Dpen]	10000/1	30 min	> 99	98.6 (S)


Example 10. Hydrogenation of dehydroaminoacids

a) Hydrogenation of methyl 2-acetamidoacrylate at Substrate/Catalyst = 1000/1



- 5 [(R)-TriOCH₂-ParaC Rh NBD]BF₄ (2.2 mg, 0.002 mmol) and methyl acetamidoacrylate (286 mg, 2 mmol) were placed in a glass liner in an Endeavour Argonaut multi-well pressure reactor. The vessel was purged with nitrogen, degassed MeOH was added (4 mL) and the reaction was pressurised to 10 bar with hydrogen. The pressure was maintained at 10 bar and the hydrogen uptake monitored. After 30 minutes the pressure was released and the reaction analysed by chiral gas-chromatography (column: Chirasil DEX-CB, method: 130°C for 10 minutes, then 15°C/min to 200°C): 100 % conversion, 99 % e.e.
- 10

b) Hydrogenation of methyl 2-acetamidoacrylate at S/C 5000/1: general procedure



- 15 The catalyst (0.001 mmol) and methyl acetamidoacrylate (716 mg, 5 mmol) were placed in a glass liner in 50 mL Parr pressure reactor. The vessel was purged with nitrogen and then with hydrogen by pressurising to 10 bar and releasing the pressure at least three times. Degassed

MeOH was added (10 mL), the reaction was purged with hydrogen as above and pressurised to 5 bar with hydrogen. The pressure was maintained between 4 and 5 bar. After 20 minutes the pressure was released and the reaction analysed by chiral gas-chromatography (column: Chirasil DEX-CB, method: 130°C for 10 minutes, then 15°C/min to 200°C).

5

The results using a series of catalysts are given below. Phanephos-based catalysts were compared with Para-C based catalysts of the present invention, demonstrating the effectiveness of the catalysts of the present invention

The stereochemistry of the product was assigned according to the results reported for


10 Phanephos-based catalysts in *J. Am. Chem. Soc.* 1997, 119, 6207.

Catalyst	Approx. time to completion	Conv. (%)	e.e. (%)
[(S)-Phanephos Rh NBD]BF ₄	30 min	100	96.7 (S)
[(R)-Phanephos Rh NBD]BF ₄	12 min	100	96.4 (R)
[(R)-HO-CH ₂ -Para-C Rh NBD]BF ₄	12 min	100	96.8 (R)
[(S)-TRIO-CH ₂ -Para-C Rh NBD]BF ₄	15 min	100	97.0 (S)
[(R)-TRIO-CH ₂ -Para-C Rh NBD]BF ₄	20 min	91	96.5 (R)
[(S)-TIPSO-CH ₂ -Para-C Rh NBD]BF ₄	10 min	100	95.0% (S)
[(R)-TIPSO-CH ₂ -Para-C Rh NBD]BF ₄	12 min	100	96.2 (R)
[rac-CH ₃ O-Para-C Rh NBD]BF ₄	15 min	100	NA
[(S)-CH ₃ O-Para-C Rh NBD]BF ₄	20 min	100	96.0 (S)
[(R)-CH ₃ O-Para-C Rh NBD]BF ₄	8 min	100	96.7 (R)
[rac-TBSO-Para-C Rh NBD]BF ₄	8 min	100	NA
[(S)-TIPSO-CH ₂ -Xyl-Para-C Rh NBD]BF ₄	5 min	100	97.2 (S)
[(S)-MeOXyl-Phanephos Rh NBD]BF ₄	5 min	100	98.0 (S)
[(S)-HO-CH ₂ - MeOXyl-Para-C Rh NBD]BF ₄	20 min	100	95.0 (S)

NA = Not Analysed


Claims.

1. A substituted paracyclophane of formula (I)




wherein X^1 and X^2 are linking groups comprising between 2 to 4 carbon atoms, Y^1 and Y^2 are selected from the group consisting of hydrogen, halide, oxygen, nitrogen, alkyl, cycloalkyl, aryl or heteroaryl, Z^1 , Z^2 and Z^3 are substituting groups that optionally contain functional groups, a , b , c , d , e and f are 0 or 1 and $a + b + c + d + e + f = 1$ to 6.

2. A substituted paracyclophane according to claim 1 wherein X^1 and X^2 are both $-C_2H_4-$.
3. A substituted paracyclophane according to claim 1 or claim 2 wherein Z^1 , Z^2 or Z^3 are non-functional group-containing substituting groups selected from branched or linear alkyl or phenyl, naphthyl or anthacyl groups.
4. A substituted paracyclophane according to claim 1 or claim 2 wherein Z^1 , Z^2 or Z^3 are functional group-containing substituting groups comprising one or more functional groups selected from halide, hydroxyl, alkoxy, carbonyl, carboxyl, anhydride, methacryl, epoxide, vinyl, nitrile, nitro, sulphate, sulphonyl, mercapto, amino, amine, imine, amide and imide.
5. A substituted paracyclophane according to any one of claims 1 to 4 wherein $a + b + c + d + e + f = 1$ or 2.
6. A substituted paracyclophane according to anyone of claims 1 to 5 wherein $a + b + c = 1$ and / or $d + e + f = 1$.
7. A method for preparation of a substituted paracyclophane of formula (I) by,




(a) performing a substitution reaction on a pseudo-ortho dibromoparacyclophane to form an intermediate substituted pseudo-ortho dibromoparacyclophane of formula (II), and



(b) reacting the substituted pseudo-ortho dibromoparacyclophane with a phosphorus compound comprising $P(Y^1Y^2)$, wherein X^1 and X^2 are linking groups comprising between 2 to 4 carbon atoms, Y^1 and Y^2 are selected from the group consisting of hydrogen, halide, oxygen, nitrogen, alkyl, cycloalkyl, aryl or heteroaryl, Z^1 , Z^2 and Z^3 are substituting groups that optionally contain functional groups, a , b , c , d , e and f are 0 or 1 and $a + b + c + d + e + f = 1$ to 6.

8. A method according to claim 7 wherein the substitution reaction is a Lewis-acid mediated electrophilic substitution reaction.


9. A substituted pseudo-ortho dibromoparacyclophane of formula (III)



X^1 and X^2 are linking groups comprising between 2 to 4 carbon atoms, Z^1 , Z^2 and Z^3 are functional group-containing substituting groups that comprise one or more functional groups selected from hydroxyl, alkoxy, carboxyl, anhydride, methacryl, epoxide, vinyl, nitrile, nitro, sulphate, sulphonyl, mercapto, sulphide amino, amine, imine, and imide, a , b , c , d , e and f are 0 or 1 and $a + b + c + d + e + f = 1$ to 6.

10. A substituted pseudo-ortho dibromoparacyclophane according to claim 9 wherein the functional group is a carboxylic acid functional group or an amino functional group.

11. A metal complex comprising the reaction product of a metal compound and a substituted paracyclophane of formula (I)




wherein X^1 and X^2 are linking groups comprising between 2 to 4 carbon atoms, Y^1 and Y^2 are selected from the group consisting of hydrogen, halide, oxygen, nitrogen, alkyl, cycloalkyl, aryl or heteroaryl, Z^1 , Z^2 and Z^3 are substituting groups that optionally contain functional groups, a , b , c , d , e and f are 0 or 1 and $a + b + c + d + e + f = 1$ to 6.

12. A metal complex according to claim 11 wherein the metal compound is a compound of palladium (Pd), platinum (Pt), rhodium (Rh), iridium (Ir) or ruthenium (Ru).
13. A metal complex according to claim 11 or claim 12 wherein the substituted paracyclophane (I) is substantially enantiomerically-pure.
14. A metal complex according to any one of claims 11 to 13 wherein the metal complex is supported on a solid support.
15. The use of a metal complex according to any one of claims 12 to 14 as a catalyst for the chiral hydrogenation of enamide and non-enamide structures, asymmetric hydrogenation in iso-quinoline synthesis, the asymmetric hydrogenation of unsaturated alcohols, asymmetric hydrogenation of ketones and imines, enantioselective isomerization of olefins, asymmetric hydroboration reactions, asymmetric cyclisation of olefinic aldehydes, asymmetric arylation and alkylation reactions and the amination of aryl halides (Hartwig-Buchwald reaction).

Abstract

A substituted paracyclophane is described of formula (I)



wherein X^1 and X^2 are linking groups comprising between 2 to 4 carbon atoms, Y^1 and Y^2 are selected from the group consisting of hydrogen, halide, oxygen, nitrogen, alkyl, cycloalkyl, aryl or heteroaryl, Z^1 , Z^2 and Z^3 are substituting groups that optionally contain functional groups, a , b , c , d , e and f are 0 or 1 and $a + b + c + d + e + f = 1$ to 6. Preferably X^1 and X^2 are $-(C_2H_4)-$ and $a + b + c + d + e + f = 1$ or 2. The substituted paracyclophane provides transition metal catalysts that demonstrate high activity and selectivity for asymmetric reactions.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.